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ABSTRACT
NOVEL VIRAL AND ASTROCYTIC CONTRIBUTORS TO EPILEPSY

Julie Chen
Stewart A. Anderson

Epilepsy is a neurological seizure disorder affecting approximately 1% of the world’s
population. Seizure disorders are numerous, heterogeneous, and can develop from a
multitude of physiological conditions including but not limited to interneuron
dysfunction, ion channel mutations, irregular development and layering of the
cerebral cortex, abnormalities in cell signaling pathways, brain tumors, traumatic
brain injuries, and mitochondrial diseases. In many seizure disorders, gene mutations
(primary) cause physiological abnormalities (secondary) that result in seizures. In
some cases, the primary cause of epilepsy remains unknown, and in other cases, the
secondary cause remains to be determined. My thesis research identified a novel,
exogenous primary contributor to epilepsy in a specific subtype of cortical
malformation disorders, as well as a secondary astrocytic irregularity resulting from a
mitochondria-related nuclear gene mutation that may contribute to epilepsy. In
Chapter 1, I briefly introduce the relationship between cortical malformation
disorders, mitochondrial disease, and epilepsy. In Chapter 2, I present data supporting
the idea that the cortical dyslamination and resultant epilepsy in focal cortical
dysplasia type IIB is caused by the human papillomavirus oncoprotein E6. In Chapter
3, I present data on astrocyte-specific irregularities resulting from mitochondrial
iii

aspartate glutamate carrier loss of function and its effects on glutamatergic
neurotransmission, and speculate on the role and importance of astrocytes in seizure
genesis and propagation.
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Chapter 1
Introduction
Epilepsy is a neurological seizure disorder defined by the recurrence of two or
more unprovoked seizures more than 24 hours apart (Fisher et al., 2014). The first
reports of epileptic patients can be traced back to Assyrian texts from 2,000 B.C.,
making epilepsy one of the oldest medical conditions described (Magiorkinis et al.,
2014). Today, more than 50 million people worldwide (approximately 1%) suffer
from epilepsy, with the incidence on the rise (Banerjee et al., 2009). The study of
epilepsy poses a unique challenge because it is a disorder with a singular set of
symptoms (seizures) that can be caused by a multitude of physiological conditions,
each of which may have their own causes. A PubMed search on causes of epilepsy
yields numerous results: interneuron dysfunction, sodium channel mutations, cortical
dyslamination, cellular signaling abnormalities, brain tumors, traumatic brain injury,
and metabolic and/or mitochondrial dysregulation (Figure 1.1). My thesis research
focused on identifying novel contributors to epilepsy and is divided into two chapters:
1) identification of a viral element that causes cortical dyslamination; and 2)
identification of an astrocytic irregularity resulting from mitochondrial dysfunction,
which may contribute to abnormal glutamate neurotransmission underlying epilepsy.
In the first part of this chapter, I introduce cortical lamination disorders and the role
that hyperactivated mammalian target of rapamycin (mTOR) signaling plays in the
development of these disorders, and subsequently, of epilepsy. In the second part of
this chapter, I discuss the neurologic effects of mitochondrial and metabolic
dysfunction and how they result in epilepsy.
1

Cortical lamination disorders, mTOR signaling, and epilepsy
Malformations of cortical development are one of the most common causes of
intractable epilepsy (Blumcke et al., 2009; Aronica et al., 2012), and can be
categorized into three groups with considerable overlap based on their causes. Group
I consists of malformations that result from abnormal neuronal and glial proliferation
or apoptosis, and includes conditions such as the megalencephalies, tuberous sclerosis
complex, and the focal cortical dysplasias. Group II describes malformations resulting
from abnormal neuronal migration, such as Pretzel Syndrome and lissencephaly.
Finally, Group III consists of malformations from abnormal postmigrational
development, such as the focal cortical dysplasias. A commonality among cortical
malformation disorders is that many of them result from the dysregulation of
signaling pathways that regulate cell size, neuronal migration, and cortical
development. One such signaling pathway that is commonly dysregulated is the
mammalian target of rapamycin (mTOR) signaling complex (Figure 1.2).
mTOR is a highly conserved, cytosolic serine/threonine kinase that is a
member of the phosphatidylinositol-3-kinase (PI3K-related protein kinase, or PIKK)
family (Abraham, 2004). First identified in 1991 in a genetic screen to identify the
protein target of the drug rapamycin (Heitman et al., 1991), mTOR functions as part
of the AMPK metabolic signaling complex to sense a cell’s nutrient, energy, and
growth factor availability to ultimately regulate its protein expression, growth, and, in
the nervous system, migration (Potter et al., 2001; Loewith et al., 2002; Potter et al.,
2002; Hahn-Windgassen et al., 2005; Ruvinsky et al., 2005). mTOR exists and
2

functions in two distinct multi-protein complexes, aptly named mTORC1 and
mTORC2 (Sarbassov et al., 2004). mTORC1 is sensitive to rapamycin and regulates
cell growth and proliferation in response to nutrient signaling and sensing. The
majority of the literature published on mTOR is focused on mTORC1, as rictor, a
protein component in mTORC2, is not conserved across species, rendering the study
of mTORC2 regulators and targets less extensive and less well understood.
Because of the role of mTOR in cell growth, proliferation, and migration, it is
essential for the development of the brain. Knocking out mTOR in the mouse results
in a defect in the formation of the telencephalon and embryonic lethality (Murakami
et al., 2004). The ablation of other proteins along the mTOR pathway also results in
embryonic or early lethality. Using nestin-Cre to create a conditional raptor knockout
mouse to study the effects of mTOR knockout on brain development, researchers
discovered that even the raptor conditional knockout mice died at early ages, with a
pronounced microcephalic phenotype underscored by reductions in cell size and cell
number (Cloëtta et al., 2013). Besides development, mTOR conditional knockout
mice have also revealed roles for mTOR in dendrite formation (Jaworski et al., 2005)
and axon elongation (Campbell and Holt, 2001).
In addition to regulating cell growth and proliferation, mTORC1 also
regulates protein translation and ribosome biogenesis through the phosphorylation of
ribosomal S6 kinase 1 and suppression of elongation factor 4E binding protein 1
(4EBP1), respectively (Pause et al., 1994; Pearson et al., 1995; Saitoh et al., 2002).
Phosphorylated S6K1 then goes on to phosphorylate the 40S ribosomal protein S6.
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Phosphorylated S6 is a commonly used readout for mTORC1 activation, and we
employ this readout in the studies conducted in Chapter 2.
Recently, researchers have identified numerous genetic mutations in
mTORC1 that underlie neurological seizure conditions. The first demonstration of an
epilepsy syndrome directly related to enhanced mTORC1 activation was tuberous
sclerosis complex (TSC), an autosomal dominant, multisystemic disorder resulting
from the loss of function of one or both negative regulators of mTOR TSC1 and
TSC2 (Baybis et al., 2004; Crino et al., 2006). TSC has been identified in all ethnic
groups, with no gender bias. It is estimated that approximately 2 million people
worldwide are affected with TSC, with 65-75% of patients harboring spontaneous de
novo mutations (Hyman et al., 2000). Patients with TSC develop benign tumors in
multiple organ systems, and brain tubers consisting of neuroglial cells exhibiting a
loss of hexalaminar organization in the brain. Over 80% of TSC patients suffer from
seizures, and it has been demonstrated that the cortical tubers are highly correlated
with epileptic foci (Evans et al., 2012).
A second example of hyperactivated mTOR signaling in seizures occurs in the
rare, neurodevelopmental disorder polyhydramnios, megalencephaly, and
symptomatic epilepsy syndrome (PMSE), or Pretzel Syndrome (Orlova et al., 2010).
Pretzel Syndrome, so named because of characteristic body posture displayed by
affected patients, results from a loss of function mutation in STE20-related kinase
adaptor alpha (STRADA), an upstream inhibitor of mTORC1. Patients with Pretzel
Syndrome display heterotopic neurons in the subcortical white matter and
subependymal regions. A recent study demonstrated STRADA loss of function4

induced deficits in neuronal migration, path finding, and polarity in vitro and altered
cortical lamination in vivo in an acute, inducible mouse model of Pretzel Syndrome,
demonstrating another link between hyperactive mTORC1 signaling, cortical
dyslamination, and epilepsy (Parker et al., 2013).
Although TSC, Pretzel Syndrome, and a number of other cortical lamination
disorders have now been associated with identifiable mutations in mTORC1, the
genetic cause for other mTORC1 hyperactive cortical malformation disorders remains
elusive. One example of this is the Group I/III disorder focal cortical dysplasia type
IIB (FCDIIB). Focal cortical dysplasia type IIB is characterized by the presence of
balloon cells – multinucleated cells with enlarged cytoplasms – which display
hyperactive mTOR signaling. In Chapter 2, I will discuss the discovery of a viral
mTOR-activating agent present only in FCDIIB brain specimens that we believe
underlies the pathogenesis of cortical dyslamination and seizures.

Mitochondrial and metabolic dysfunction and epilepsy
Mitochondrial diseases are multisystemic disorders caused by abnormal
metabolic pathways within the mitochondria, which result in decreased energy
production. Mitochondrial diseases can result from either an inherited gene mutation,
or through de novo mutations in mitochondrial proteins (inborn errors of metabolism).
There are now over 500 identified inborn errors of metabolism (Saudubray et al.,
2006), with an overall incidence 1:1000 (Campeau et al., 2008). The most common
presentation of mitochondrial disease, inherited or congenital, is encephalomyopathy
(Schmiedel et al., 2003), which is highly co-morbid with seizures and epilepsy.
5

Different epilepsy phenotypes have been described that result from inborn errors of
metabolism or de novo or inherited mutations in mitochondrial DNA (most often in
the enzymatic complexes that comprise the oxidative phosphorylation machinery) or
mitochondria-related nuclear gene mutations (Khurana et al., 2013).
The most well-known mitochondrial DNA-related epilepsy syndromes is
mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes
(MELAS), which can result from mutations in complex I, V, or the mitochondrially
encoded transfer RNAs histidine, leucine 1, or valine. First characterized in 1984
(Pavlakis et al., 1984), mutations that cause MELAS often result in a build up of
lactic acid, which results in muscle weakness, headaches, gastrointestinal issues, and
seizures (Hirano and Pavlakis, 1994). Another mitochondrial DNA-related epilepsy
syndrome is myoclonic epilepsy and ragged red fibers (MERRF), a condition
resulting most often from mutations in mitochondrial transfer RNA lysine, as well as
in leucine 1, histidine, and serine 1. Epilepsy is the defining characteristic of MERRF
(Fukuhara et al., 1980), with patients presenting with progressive myoclonus or
generalized tonic-clonic seizures (Berkovic et al., 1989). Lastly, Kearns-Sayre
syndrome is a multisystemic disorder resulting from large mitochondrial DNA
mutations that affects approximately 3 in 100,000 individuals. Mitochondrial DNA
mutation deletions that cause Kearns-Sayre are often associated with proteins
involved in oxidative phosphorylation. Epileptic seizures in MELAS, MERRF, and
Kearns-Sayre syndrome can include myoclonic, tonic-clonic, absence, or status-like
seizures, and patients frequently display more than one seizure type.

6

Though complex II is the only member of the enzymatic oxidative
phosphorylation machinery fully encoded by nuclear DNA, the fact is nuclear DNA
also encodes many other mitochondrial proteins, including components of the other
oxidative phosphorylation complexes. The most common nuclear-encoded
mitochondrial gene mutation occurs in the POLG gene, which encodes the catalytic
subunit of the mitochondrial DNA polymerase. Mutations in POLG result in Alpers’
disease, a condition of severe intractable seizures occurring early in life with
intellectual disability and hypotonia, ataxic neuropathies, and chronic progressive
external ophthalmoplegia (Naviaux and Nguyen, 2004; Van Goethem et al., 2003;
Van Goethem et al., 2001). Other mutations in nuclear-encoded mitochondrial
proteins often result in the deletion of large segments of mitochondrial DNA or
damage of mitochondrial DNA due to defective nucleotide exchange across the
mitochondrial membrane. The encoded nuclear proteins include but are not limited to
thymidine phosphorylase, adenine nucleotide translocator 1, and TWINKLE (Nishino
et al., 1999; Kaukonen et al., 2000; Spelbrink et al., 2001).
Despite the knowledge that patients with mitochondrial mutations have
epilepsy, the cause and effect relationship between mitochondrial mutations and
epilepsy is highly debated. On the one hand, mitochondrial dysfunction results in
diminished ATP output and altered calcium homeostasis, both of which have effects
on neuronal excitability and seizure susceptibility. On the other hand, prolonged
seizures can result in mitochondrial oxidative stress and free radical production. In a
whole genome mitochondrial DNA sequencing study of temporal lobe epilepsy
patients, researchers found that the majority of heteroplasmic mitochondrial DNA
7

mutations was highly congregated to the epileptic region of the hippocampus,
suggesting that mitochondrial mutations are the underlying pathology for seizures in
temporal lobe epilepsy (Azakli et al., 2013). In Chapter 3, I will discuss the cellspecific effects contributing to seizures of the loss of function of a nuclear-encoded
mitochondrial protein, Slc25a12.

8

Figure 1.1. Epilepsy is a seizure disorder resulting from many different
physiological conditions.

9

Figure 1.2. The mTOR signaling cascade.
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Focal cortical dysplasia type IIB (FCDIIB) is a sporadic developmental
malformation of the cerebral cortex highly associated with pediatric epilepsy. Balloon
cells (BCs) in FCDIIB exhibit constitutive activation of the mammalian target of
rapamycin complex 1 (mTORC1) signaling pathway. Recently, the high-risk human
papillomavirus type 16 oncoprotein E6 was identified as a potent activator of
mTORC1 signaling. Here, we test the hypothesis that HPV16 E6 is present in human
FCDIIB specimens. HPV16 E6 protein was robustly expressed in all FCDIIB
specimens in BCs, but not in regions without BCs or in control tissue specimens
including normal brain, lymphoblasts, fibroblasts, cortical tubers, and u87 glioma
cells. E6 expression in FCDIIB colocalized with phosphactivated S6 protein, a known
mTORC1 substrate. HPV16 E6 DNA and mRNA were detected in representative
specimens of FCDIIB but not control cortex, and were confirmed by sequencing.
Transfection of E6 into fetal mouse brains caused a focal cortical malformation in
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association with enhanced mTORC1 signaling. Our results indicate a new association
between HPV16 E6 and FCDIIB and demonstrate for the first time HPV16 E6 in the
human brain. We propose a novel etiology for FCDIIB based on HPV16 E6
expression during fetal brain development.
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Introduction
Focal cortical dysplasia type IIB (FCDIIB) is a sporadic developmental
malformation of the cerebral cortex that is a common cause of pediatric epilepsy.
FCDIIB is characterized by disorganized laminar architecture and enlarged,
dysmorphic cells called balloon cells (BCs) (Blumcke et al., 2011), which exhibit
constitutive activation of the mammalian target of rapamycin complex 1 (mTORC1)
signaling pathway (Crino, 2011). Although aberrant mTORC1 activation can be
caused by genetic mutations in upstream mTOR effectors, the etiology of mTORC1
activation in BCs is unknown. We have previously proposed that FCDIIB is part of a
pathological spectrum of developmental disorders (mTORopathies) associated with
abnormal cortical architecture, seizures, and enhanced mTOR signaling that includes
tuberous sclerosis complex (TSC), hemimegalencephaly, and ganglioglioma (GG)
(Crino, 2011; Crino 2007).
High-risk human papillomavirus type 16 (HPV16) is the most common cause
of cervical cancer (Faridi et al., 2011) in women and has been linked to a growing
number of cases of oropharyngeal cancer (Bishop and Westra, 2011). Interestingly,
the cytopathic effect of HPV16 infection on cervical epithelium results in the
formation of koilocytes—enlarged cells with multilobulated nuclei—also called BCs
(McLeod, 1987). The E6 oncoprotein encoded by HPV16 can be detected in clinical
samples, and detection of HPV16 E6 DNA and mRNA by polymerase chain reaction
(PCR), reverse transcriptase PCR (RT-PCR), or in situ hybridization (ISH) is
considered diagnostic of HPV16 infection (Zaravinos et al., 2009). Recent work has
shown that the HPV16 E6 oncoprotein activates mTORC1 signaling at distinct steps:
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first by binding to TSC2 and targeting it for ubiquitin-mediated degradation (Lu et al.,
2004), and second by activating PDK1 and Akt (Spangle and Munger, 2010)
upstream of TSC1/TSC2. In both mechanisms, mTORC1 activation is evidenced by
enhanced phosphorylation of the ribosomal S6 protein (phospho-S6), as in cervical
cancer (Zhou et al., 2007). We found the effects of HPV16 E6 on mTORC1 signaling
to be strikingly similar to previous reports demonstrating reduced levels of TSC2
(Grajkowska et al., 2008), enhanced phospho-PDK1 and phospho-Akt levels (Schick
et al., 2007), and enhanced mTORC1 signaling in BCs (Crino, 2011) in FCDIIB. To
date, there is no evidence that HPV16 can infect the brain, although HPV16 has been
detected in peripheral nerves adjacent to oropharyngeal cancers (Fule et al., 2006) and
transgenic mice expressing E6 and E7 oncoproteins develop anaplastic brain tumors
(Arbeit et al., 1993). However, based on the cytopathic and cell signaling similarities
between cervical dysplasia and FCDIIB, we hypothesized that HPV16 E6 DNA,
mRNA, and protein are present in human FCDIIB brain specimens and could serve as
a pathogenic agent in FCDIIB. We further hypothesized that expression of E6 would
overlap with markers of mTORC1 hyperactivation and that introduction of E6 into
fetal mouse brain would cause alteration of cortical architecture.

Results
Detection of HPV16 E6
Antibodies recognized HPV16 E6 by immunocytochemistry in the CaSki
HPV16 cervical cancer cell line, known to contain E6 (Figure 2.1A, B), as
demonstrated previously (Herfs et al., 2012). In contrast, Western assay of fibroblast
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and immortalized lymphoblastoid cell lines generated from normal control
individuals and patients with TSC—an autosomal dominant disorder with brain
histopathology similar to FCDIIB—did not express E6 protein, nor did U87 and
U87vIII glioma lines (Figure 2.1C). E6 protein was not detected in normal human
postmortem brain tissue (n=4) using 3 E6 antibodies (Figure 2.1D, E).
In all 50 histopathologically confirmed specimens of FCDIIB (20 females, 30
males; see Table 2.1; Supplementary Figure 2.1; Supplementary Table 2.1), there was
robust cytoplasmic expression of E6 primarily in BCs in the subcortical white matter
and cortical mantle that was detected by E6 ab70 and confirmed with 2 additional
antibodies (Figure 2.2). In accordance with varying degrees of pathological
heterogeneity in FCDIIB, subregions of some specimens did not contain BCs, and
these regions did not exhibit E6 expression. However, regions with high BC numbers
showed extensive E6 expression (Figure 2.1A, border zone, arrows). Similar to
quantification of other established BC protein markers (Lamparello et al., 2007), cell
count analyses in 10 representative FCDIIB specimens revealed that on average, 79%
of morphologically defined BCs expressed E6 (Supplementary Figure 2.2). E6
expression was highly specific for and exclusively linked to FCDIIB histopathology
and was not detected in 36 control brain specimens including temporal lobe epilepsy
specimens with no evidence of FCD (n=9), or in 5 other types of epilepsy-associated
brain malformations including tuberous sclerosis complex (see Table 2.2;
Supplementary Figure 2.3). “No primary’’ antibody and ubiquitous IgG1 isotype
immunohistochemical controls did not yield an immunohistochemical reaction
(Supplementary Figure 2.4). Interestingly, as has been demonstrated in many cervical
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dysplasia specimens (Gatta et al., 2011) and peripheral nerve adjacent to
oropharyngeal cancer (Fule et al., 2006), the L1 capsid protein was not detected by
immunohistochemistry (data not shown).
p16INK4a, a cyclin-dependent kinase inhibitor highly associated with HPV
infection in cervical and oropharyngeal cancers (Kostopoulou et al., 2011), was
detected immunohistochemically within BCs in all FCDIIB cases analyzed (n=20),
but not in surrounding brain tissue without BCs (Figure 2.3) or in control brains.
Additionally, because p53 degradation occurs in cervical cancers (Gatta et al., 2011)
and is promoted by E6 (Doorbar, 2006; Scheffner et al., 1990), we examined p53
expression. Contrary to previous reports (Chamberlain and Prayson, 2008), we found
low p53 expression in astrocytes within the lesions and no expression in BCs
(Supplementary Figure 2.5).

Colocalization of E6 and Phosphoactivated mTORC1 Substrates in FCDIIB
Next we hypothesized that E6 expression, if pathogenic through enhanced
mTORC1 signaling, should colocalize in cells exhibiting mTORC1 activation.
Double fluorescence immunohistochemistry was performed on FCDIIB specimens
using antibodies against E6 and phospho-S6 (Ser235/236), a robust biomarker for
mTORC1 activation in FCDIIB (Orlova et al., 2010). Phospho-S6 and E6 proteins
were highly coexpressed in BCs (Figure 2.4A–C). A few cells expressing E6 did not
exhibit phospho-S6 (see Figure 2.4D, arrow), but virtually all of the phospho-S6
labeled cells expressed E6. In further support of our data, cortical tubers, which
exhibit mTORC1 activation as a consequence of either mutations in TSC1 or TSC2
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(but not E6 expression), did not exhibit E6 immunoreactivity. mTORC1 activation is
not a feature of control brain tissue, FCDI, and MCD; this was supported by the
absence of E6 in these tissues.

HPV16 E6 DNA
Template DNA was extracted in blinded fashion from 11 randomly selected
FCDIIB specimens containing E6-labeled BCs and 19 control brain specimens with
no E6 detection (see Supplementary Table 2.1). Viral cross-contamination of tissue
blocks was unlikely, as specimens were sectioned in 3 different pathology
laboratories. From equal quantities of template DNA, HPV16 E6-specific primers
amplified a 477bp amplicon, confirmed by sequencing to be HPV16 E6 (homology,
97–99%; National Center for Biotechnology Information #U34127), in all FCDIIB
specimens but not in control brain specimens, an HPV-negative cervical cancer cell
line, C33A, or in a no template control reaction (Figure 2.5A, top). The sequences
amplified from our patient samples contain variations that are distinct from published
E6 sequence (Seedorf et al., 1985), suggesting that our amplicons were distinct and
not a uniform contaminant. As most of our sample was from individuals of Northern
European decent, it is not surprising that we find European prototype variant E-G350
(T350G) as the uniform isotype. As further corroboration of HPV16 infection, the
HPV16 E7 gene, an oncogene directly adjacent to E6 in the HPV16 genome, and
upstream long control region were also detected in FCDIIB cases by PCR
(Supplementary Figure 2.6).
We then show that HPV16 viral DNA can be visualized in the FCDIIB
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specimens by ISH. FCDIIB specimens (n=7) were probed with a biotinylated HPV
DNA probe that hybridizes robustly to HPV16 DNA in CaSki and SiHa cells
(Montag et al., 2011), and visualized with DAB (Evans et al., 2003). HPV16 DNA
was detected in BCs of all FCDIIB specimens, but it was not present in regions of
FCDIIB with no BCs, or in control brain tissue (n=6, see Figure 2.5B–H and
Supplementary Figure 2.7) (Montag et al., 2011).

mRNA
Total RNA was extracted in a blinded fashion from 12 randomly selected
FCDIIB specimens containing E6-labeled BCs and 17 controls. RT-PCR using
specific primer pairs designed to detect full-length HPV16 E6 and its known splice
variants (E6*I and E6*II) detected E6 mRNA in all selected representative FCDIIB
specimens (see Figure 2.5A, bottom) but not in any of the controls. Whereas E6
splice variants were detected in CaSki cells, only full-length E6 transcript was
detected in FCDIIB tissue. The detection of E6 transcript by RT-PCR provides a
critical diagnostic link between detection of viral DNA and encoded protein and
strongly supports the presence of HPV16 E6 in FCDIIB.

HPV16 E6 Expression in Neuroglial Progenitor Cells Disrupts Cortical Lamination
To functionally link E6 expression with the development of cortical
malformations, we next tested the hypothesis that expression of E6 protein in
neuroglial progenitor cells during fetal brain development disrupts cortical
lamination. A plasmid encoding E6 was cotransfected with an RFP reporter plasmid
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into fetal mouse brains (n=3) at embryonic day 14 (ED14) by in utero electroporation
(Saito, 2006). Progenitor cells born on ED14 achieve a cortical laminar destination of
layer II–III by ED19, and brains transfected with RFP plasmid alone exhibited RFP+
cells in layer II–III at ED19 (Figure 2.6A; Supplementary Figure 2.8). Histological
examination of the cotransfected brains on ED19 by fluorescence microscopy
revealed a focal cortical malformation where 74% of RFP+ cells—all of which were
E6 immunoreactive—failed to reach their appropriate layer II–III destination and
accumulated in the subcortical white matter and ventricular/subventricular (VZ/SVZ)
zones (see Figure 2.6B, C). Overt cytomegaly was not observed. In cotransfected
brains, RFP+ neurons that reached cortical layer II–III were not E6 immunoreactive
(Figure 2.6D). Colabeling with phospho-S6 revealed that most transfected RFP+ cells
within the focal malformation in the VZ/SVZ zones expressed phospho-S6
(Supplementary Figure 2.9). These results demonstrate that E6 expression in neural
progenitor cells during fetal brain development alters cortical lamination in
association with enhanced mTORC1 activation.

Conclusions and Discussion
We demonstrate the presence of HPV16 E6 DNA, mRNA, and protein in BCs
in FCDIIB. There was a high concordance between the localization of E6 protein and
the phosphoactivated mTORC1 substrate S6 in BCs, suggesting a functional link
between HPV16 E6 and mTORC1 activation in FCDIIB. Indeed, introduction of E6
into fetal mouse brain at ED14 causes a developmental malformation of the brain,
associated with enhanced mTORC1 signaling. Although further investigation is
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warranted to understand how FCDIIB causes epilepsy, our findings suggest a new
pathogenesis for FCDIIB based on localized central nervous system HPV16 infection
during fetal brain development that accounts for many of the known features of
FCDIIB, including sporadic occurrence, enhanced mTORC1 signaling (Crino, 2011),
and altered brain cytoarchitecture. Our study is the first to provide an association
between HPV16 infection and a neurological disorder and the first to detect HPV16
in human brain.
The standard detection methods for HPV16 in cervical dysplasia and cancer as
well as oropharyngeal cancer include PCR, RT-PCR, ISH, and proprietary,
commercially available capture assays. For example, the landmark paper reporting
HPV16 in head and neck cancer detected HPV16 by PCR and ISH (Gillison et al.,
2000). Our approach included PCR, RT-PCR, ISH, and immunohistochemistry and
thus implemented methodologies that are widely believed to represent the gold
standards for HPV16 detection (Zaravinos et al., 2009). The E6 antibodies detected
E6 protein in a well-described cervical cancer cell line (CaSki cells), but not in a
variety of human lymphoblast, fibroblast, or glioma cell lines as well as normal
control brain and several other types of brain malformation associated with epilepsy.
We further find that pINK4a, a cell-signaling protein that is activated by E7 (also
detected in our samples), is expressed in FCDIIB. Taken together, these data provide
strong support for the presence of HPV16 E6 in FCDIIB. HPV16 E6 is commonly
detected in the nucleus and cytoplasm; E6 DNA has been reported in the cytoplasm,
nucleus, or both in cervical dysplasia (Gatta et al., 2011; Montag et al., 2011; Burns et
al., 1987; Pillai et al., 1999) and in peripheral nerves adjacent to oropharyngeal
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cancer (Fule et al., 2006).
Our findings in human FCDIIB tissue are supported by expression of E6 in
fetal mouse brain causing disruption of cortical architecture. Although BCs were not
detected, a limitation of in utero electroporation assay is the duration of the
transfection effect, with E6 being expressed for only 4 to 5 days (from ED14 to
ED19). In human patients, the genesis of BCs may take much longer to occur. We
acknowledge that a transient transfection of E6 in the mouse brain for 5 days likely
cannot fully replicate human FCDIIB, and clearly future studies will be needed to
examine the cellular phenotype, lineage, and excitability of the transfected cells.
Nonetheless, our data demonstrate that expression of E6 in the fetal mouse brain leads
to aberrant cortical lamination and supports the hypothesis that E6 may be a
pathogenic agent in FCDIIB.
We submit that it is highly unlikely that our results reflect artifactual
contamination of the resected specimens or laboratory reagents. For example, the
FCDIIB brain tissue specimens were resected under sterile surgical conditions during
epilepsy surgery and taken immediately from the operating room to the pathology
area in designated sterile tubes, where they were immediately fixed in formalin. HPV
is not known to be an aerosolized virus and, for example, is not detected outside of
areas in which gynecological procedures are performed (Strauss et al., 2002). We did
not detect HPV16 in control specimens under blinded conditions, and HPV16 was not
detected in a known cancer cell line (C33A) that does not contain HPV16. We did not
detect the capsid protein L1 in our samples using immunohistochemistry; however, in
mid to later stage cervical dysplasia, L1 is often not detected (Gatta et al., 2011). The
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absence of L1 in FCDIIB is similar to results in peripheral nerves expressing E6
adjacent to oropharyngeal carcinoma (Fule et al., 2006). Other genomic components
of HPV16 such as E1 and E4 may not be detected in middle to late stage cervical
dysplasia (Doorbar, 2006). Interestingly, severe cervical dysplasia and cervical cancer
contain integrated HPV genomes expressing exclusively E6 and E7 rather than
episomes capable of producing more assembled virus.
One pivotal unresolved issue is the mode of HPV16 transmission in FCDIIB.
Because it is believed that FCDIIB forms during embryonic brain development, a
possibility is transplacental HPV16 infection of progenitor cells in the developing
brain. Typically, HPV16 infects basal epithelial cells in the cervix to initiate the viral
life-cycle and infection via putative interactions with cell surface heparan sulfate
proteoglycans such as syndecan-1 and glypican, which are widely expressed on
squamous epithelial cells. However, syndecan-1 is highly expressed on neural
progenitor cells in the embryonic mouse brain (Ford-Perriss et al., 2003), thus
providing a potential mechanism for viral entry. The transplacental HPV transmission
rate among women with either known HPV infection, an abnormal Papanicolaou
smear, or genital warts has been reported as 12.2% (Rombaldi et al., 2008). Thus,
because the prevalence of HPV infection is estimated at 26.8% (Dunne et al., 2007)
among females aged 14 to 59 years in the United States, and in many women HPV16
infection is asymptomatic (Tota et al., 2011), transplacental spread of HPV16 is a
plausible mechanism for entry into the brain during early fetal cortical development,
even in the absence of overt clinical infection. Indeed, a recent study demonstrated
that sporadic fetal brain malformations (e.g., dysplasias) could be detected as early as
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24 weeks gestation by magnetic resonance imaging (Righini et al., 2012).
Alternatively, it is conceivable that the effects of HPV16 E6 could lead to FCDIIB
formation in the early neonatal period.
Although the detection of E6 in FCDIIB provides a new insight into the
pathogenesis of this brain malformation, the mechanism by which HPV16 might
cause epilepsy remains to be defined. Furthermore, although we sampled a small
number of additional brain malformation subtypes and did not detect E6, it remains
possible that HPV16 may be pathogenic in other forms of cortical malformation.
Clearly, future epidemiological investigation will be necessary to define the extent,
modes, and temporal course of HPV16 transmission into the developing brain.

Experimental Procedures
Brain Specimens
FCDIB, FCDIIA, FCDIIB, GG, mild malformation of cortical development
(mMCD), temporal lobe epilepsy, and TSC brain tissues (Tables 2.1 and 2.2) were
obtained following surgical resection (Academic Medical Center, Amsterdam, the
Netherlands; University College London, London, UK, courtesy of S. Sisodiya;
University of Pennsylvania Medical Center, Philadelphia, PA) for intractable
epilepsy. Normal control brain tissues were obtained at postmortem examination
(National Disease Research Interchange, Philadelphia, PA; Developmental Tissue
Bank, University of Maryland, Baltimore, MD). Specimens were fixed in 4%
paraformaldehyde, embedded in paraffin, and sectioned at 6 to 10 µm in 3 distinct
pathology laboratories. All human tissue was obtained in accordance with an
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approved institutional review board protocol.

Cell Culture
Immortalized lymphoblasts and fibroblasts derived from normal control
individuals, and patients with known mutations in either TSC1 or TSC2, were
obtained from Coriell (Camden, NJ). CaSki (CRL-1550) and C33A (CRM-HTB-31)
cervical cancer cell lines were obtained from the American Type Culture Collection
(Manassas, VA). Immortalized lymphoblasts were cultured in RPMI-1640 media
(Invitrogen, Grand Island, NY), 15% fetal bovine serum (FBS), 2mM L-glutamine.
Immortalized fibroblasts were cultured in modified Eagle medium (MEM; Invitrogen,
Grand Island, NY) supplemented with 15% FBS and 2 mM L-glutamine. U87 glioma
cells were obtained courtesy of D. O’Rourke, Perelman School of Medicine and were
cultured in Dulbecco MEM supplemented with 1% FBS and 1%
penicillin/streptomycin. CaSki cells were cultured in RPMI-1640 media (Invitrogen)
supplemented with 10% FBS and 1% penicillin/streptomycin. C33A cells were
cultured in MEM supplemented with 10% FBS.

Immunohistochemistry
Brain sections were probed with antibodies recognizing E6 (ab70, Abcam,
Cambridge, MA; MA1-46057, Thermo Scientific, Waltham, MA; sc-1583, Santa
Cruz Biotechnology, Santa Cruz, CA), phospho-S6 (108D2; Cell Signaling
Technology, Danvers, MA), p16INK4a (ab54210, Abcam), or p53 (ab26, Abcam)
overnight at 4 degrees in TRIS buffer pH 7.4/2% fetal bovine serum), incubated in
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biotinylated secondary antibody, and visualized using avidin–biotin conjugation
(Vectastain ABC Elite, Vector Laboratories, Burlingame, CA or Powervision Kit,
Immunologic, Duiven, the Netherlands) with 3,3’-diaminobenzidine under light
microscopy. For double-labeling studies, after incubation with primary antibodies,
sections were incubated for 2 hours with Alexa Fluor 568 and Alexa Fluor 488
(antirabbit immunoglobulin G [IgG] or antimouse IgG; 1:200; Molecular Probes,
Eugene, OR) and visualized with a laser scanning confocal microscope (SP2, argonion laser; Leica, Wetzlar, Germany). All immunostained sections were assessed in a
blinded fashion independently by 2 observers.

PCR
DNA was extracted from FCDIIB specimens exhibiting E6 expression (see
Results) and from control sections without evidence of E6 expression (QIAamp DNA
FFPE Tissue Kit; QIA- GEN, Valencia, CA). Equal amounts of template genomic
DNA were used for PCR in designated PCR-safe, contaminant-free stations. Primers
amplifying the entire HPV16 E6 coding regions (5’ATGCACCCAAAGAGAACTGCA-3’ forward; 5’ATTACAGCTGGGTTTCTCTACG-3’ reverse) were used to detect viral genomic
DNA brain specimens. DNA was subjected to 35 cycles of PCR amplification.
Amplicons were resolved on a 1.5% agarose gel and were sequenced at the PENN
Sequencing Facility.

In Situ Hybridization
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Detection of HPV DNA in situ in resected tissue sections was accomplished
using GenPoint HPV Biotinylated DNA Probe recognizing genomic clones of several
HPV isotypes, including HPV16 and 18, that account for >90% of cervical cancers
(Dako, Carpinteria, CA) and GenPoint Tyramide Signal Amplification System for
Biotinylated Probes (Dako). In situ hybridization was achieved as previously
described15 with the addition of 200 µg/ml proteinase K in water and 1:50
diaminobenzidine (DAB) for 5 minutes, and visualized under light microscopy.
Assessment of the sections was performed in a blinded fashion by 2 investigators.

RT-PCR
RNA was extracted from tissue sections (RNeasy FFPE Kit; QIAGEN).
Synthesis of cDNA and RT-PCR were performed (OneStep RT-PCR Kit; QIAGEN).
RT-PCR primers amplifying full-length HPV16 E6 cDNA and known splice variants
E6*I and E6*II were used (5’-AATGTTTCAGGACCCAC AGG-3’ forward; 5’CAGCTGGGTTTCTCTACGTGTTC-3’ reverse). RNA was subjected to 40 rounds
of PCR amplification after cDNA synthesis. Amplicons were resolved on a 1.5%
agarose gel and were sequenced at the PENN Sequencing Facility.

In Utero Electroporation
Introduction of plasmid cDNAs by in utero electroporation into fetal C5BL/6
mice (Charles River, Wilmington, MA) on embryonic day (ED) 14 was achieved as
reported previously.16 E6 (plasmid 8641; Addgene, Cambridge, MA) and red
fluorescent protein (RFP) plasmids (5 µl each) were microinjected into the lateral
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ventricle of fetal mouse brains (n=3). In control mice, an RFP-only plasmid was
injected (n=5). Following microinjection, the lateral aspects of the brain were
exposed to a brief electrical field pulse (40V) by a forceps-type electrode
(CUY21EDIT Square Wave Electroporator; Sonidel, Dublin, Ireland) to effect
passage of the plasmid into cells. Embryos were euthanized at ED19. Brains were
flash frozen on dry ice, and 10 µm sections were probed with E6 and phospho-S6
antibodies. Sections were visualized by fluorescence (DM4000 B microscope, Leica)
or confocal (LSM510; Zeiss, Thornwood, NY) microscopy. Animal experiments were
performed in accordance with an approved institutional animal care and use
committee protocol.
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Figure 2.1. E6 is detected in CaSki cervical cancer cells.
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Figure 2.1. E6 is detected in CaSki cervical cancer cells.
A) With ab70 antibody
B) With sc-1583 antibody. Cytoplasmic staining can be seen as well. Scale bar = 50
µm.
C) Western assay depicting absence of E6 protein expression in immortalized
lymphoblasts and cultured fibroblasts from normal control individuals and
patients with tuberous sclerosis complex (TSC), as well as U87 glioma cell lines.
Protein loading was confirmed with glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). GBM indicates glioblastoma multiforme.
D) Absence of E6 expression in control brain specimens.
E) Absence of E6 expression in control brain specimens.
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Figure 2.2. E6 immunoreactivity in 6 distinct focal cortical dysplasia type IIB
specimens.
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Figure 2.2. E6 immunoreactivity in 6 distinct focal cortical dysplasia type IIB
specimens.
A) E6 expression in balloon cells, but not overlying cortex (border zone, arrows).
Scale bar = 250 µm.
B) E6 expression in balloon cells. Scale bar = 100 µm.
C) E6 detected and visualized with high magnification. Scale bar = 75 µm.
D) E6 detected and visualized with high magnification. Scale bar = 75 µm.
E) E6 detected and visualized with high magnification. Scale bar = 100 µm.
F) E6 detected and visualized with high magnification. Scale bar = 75 µm.
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Figure 2.3. p16INK4a immunoreactivity in focal cortical dysplasia type IIB
(FCDIIB) balloon cells (BCs).
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Figure 2.3. p16INK4a immunoreactivity in focal cortical dysplasia type IIB
(FCDIIB) balloon cells (BCs).
A) Phase contrast light microscopy depicting absent p16INK4a immunoreactivity in
control cerebral cortex. Neurons in A can be seen without p16INK4a labeling
(arrows). Scale bar = 100 µm.
B) p16INK4a immunoreactivity in FCDIIB BCs. Scale bar = 100 µm.
C) p16INK4a in nucleus of BC (arrow). Scale bar = 200 µm.
D) Minimal p16INK4a expression in cortex surrounding FCDIIB with no BCs. Scale
bar = 100 µm.
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Figure 2.4. Coexpression of E6 and phosphorylated S6 proteins in focal cortical
dysplasia type IIB (FCDIIB).
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Figure 2.4. Coexpression of E6 and phosphorylated S6 proteins in focal cortical
dysplasia type IIB (FCDIIB).
A) Balloon cells in FCDIIB express both E6 (green) and phosphor-S6 (red) proteins
(arrows). DAPI nuclear stain is shown in blue. Scale bar = 25 µm.
B) Balloon cells in FCDIIB express both E6 (green) and phosphor-S6 (red) proteins
(arrows). DAPI nuclear stain is shown in blue. Scale bar = 25 µm.
C) Balloon cells in FCDIIB express both E6 (green) and phosphor-S6 (red) proteins
(arrows). DAPI nuclear stain is shown in blue. Scale bar = 25 µm.
D) Rare cells express E6 only within minimal phosphor-S6 colabeling (arrow). Scale
bar = 25 µm.
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Figure 2.5. E6 DNA and mRNA detection in focal cortical dysplasia type IIB
(FCDIIB) specimens by polymerase chain reaction (PCR), reverse transcriptase
PCR (RT-PCR), and in situ hybridization.

40

Figure 2.5. E6 DNA and mRNA detection in focal cortical dysplasia type IIB
(FCDIIB) specimens by polymerase chain reaction (PCR), reverse transcriptase
PCR (RT-PCR), and in situ hybridization.
A) E6 DNA and mRNA are detected by PCR and RT-PCR in CaSki cells (lower
molecular weight bands in RT-PCR represent E6 splice variants) and 8 different
representative FCDIIB specimens, but not in control brain, C33A cells, or no
template control.
B) E6 detection by in situ hybridization in nuclei and cytoplasm of balloon cells.
Scale bar = 125 µm.
C) E6 detection by in situ hybridization in nuclei and cytoplasm of balloon cells.
Scale bar = 80 µm.
D) E6 detection by in situ hybridization in nuclei and cytoplasm of balloon cells.
Scale bar = 80 µm.
E) E6 detection by in situ hybridization in nuclei and cytoplasm of balloon cells.
Scale bar = 125 µm.
F) E6 detection by in situ hybridization in nuclei and cytoplasm of balloon cells.
Scale bar = 80 µm.
G) E6 detection by in situ hybridization in nuclei and cytoplasm of balloon cells.
Scale bar = 125 µm.
H) Absent hybridization signal in control cortex. Pial surface is depicted by arrow.
Scale bar = 125 µm.
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Figure 2.6. E6 transfection in utero causes a focal cortical malformation.
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Figure 2.6. E6 transfection in utero causes a focal cortical malformation.
A) Red fluorescent protein (RFP)+ cells achieve appropriate laminar destination
(layer II/III) following in utero electroporation with RFP plasmid alone (see also
Supplementary Figure 2.8). Scale bar = 100 µm.
B) Focal cortical malformation at embryonic day 19 following in utero
electroporation of E6 and RFP plasmids (arrows). Scale bar = 100 µm.
C) Cells retained within the ventricular/subventricular zones coexpress RFP and E6
(inset, higher magnification). Scale bar = 100 µm.
D) In cotransfected brains, cells reaching the cortical plate do not express E6. In
bottom panel, confocal microscopy demonstrating cellular colocalization of E6
and RFP within the focal malformation depicted in C. Scale bar = 100 µm.
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Table 2.1. HPV E6 protein is detected in 50 FCDIIB specimens.
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Table 2.2. Absence of E6 in non-FCDIIB cases.
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Supplemental Figure 2.1. FCDIIB specimens exhibiting nestin (a-b) and vimentin
(c) immunoreactivity. Note that most BCs exhibit robust nestin and vimentin
expression. Scale bar: 150 µm (a,c); 100 µm (b).
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Supplemental Figure 2.2. Percentage of BCs that express E6. Morphologically
dlefined BCs from 10 representative cases were examined at high magnification (40x)
for total BC counts. E6 expression in each BC was determined as present or absent
and the percentage of morphologically identified BCs that expressed E6 protein was
calculated.
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Supplemental Figure 2.3. Absent E6 immunoreactivity in human TSC speciments.
Cortical tubers (a-c), subependymal giant cell astrocytoma (d). Scale bar: 150 µm (a,
c), 100 µm (b, d).
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Supplemental Figure 2.4. Immunohistochemistry control experiments. No primary
(E6) antibody controls (a-b). Isotype IgG antibody with no primary (E6) added (c-d).
Note absence of immunolabeling in balloon cells (arrows). Scale bar = 150 µm.
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Supplemental Figure 2.5. p53 expression in FCDIIB. p53 immunoreactive
astrocytes in FCDIIB specimens (a). Absence of p53 immunoreactivity in BCs (b,
arrow). Scale bar: 200 µm.
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Supplemental Figure 2.6. PCR in representative FCDIIB cases for HPV16 E7 and
HPV16 LCR revealed 297bp and 439bp amplicons. DNA sequencing confirmed the
identity of viral elements and BLAST against HPV16 E7 and LCR sequence revealed
98% sequence similarity.
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Supplemental Figure 2.7. HPV DNA is not present in control brain (a) and regions
of FCDIIB specimens with no balloon cells (b-c) by in situ hybridization. Note single
neuron (b; arrow). Small arrows in a and c depict the pial surface.
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Supplemental Figure 2.8. In utero electroporation of RFP plasmid does not disrupt
normal cortical lamination. Transfection of RFP plasmid on embryonic day 14 by in
utero electroporation labels a population of cells destined for layer II-III (a). Colabeling with Cux1 antibody reveals normal expression of Cux1 protein in transfected
layer II-III cells (b). Hoechst labeling demonstrates laminar organization of the cortex
(c). Composite photomicrograph showing direct overlay of RFP and Cux1 in layer IIIII (d). Scale: 100 µm.
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Supplemental Figure 2.9. Three dimensional confocal microscopy demonstrates colocalization of RFP and phosphor-S6 (P-S6) protein in cells within the subventricuar
zone following electroporation with RFP and E6 plasmids. Three RFP transfected
cells are shown. The cells at right and left exhibit P-S6 immunoreactivity (green),
shown in overlay on far right; the center cell does not show phosphor-S6 labeling.
Cross sectional image for this cell is depicted in left panels (L); apical view of both
cells represented in top panels (T).
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Supplemental Table 2.1. Table detailing detection assays conducted on FCDIIB or
control cases. Check mark denotes assay was performed.
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Chapter 3
Astrocytic apoptosis and contributions to seizures in
Slc25a12 mutant mice
Slc25a12 is a mitochondrial aspartate-glutamate carrier that promotes the
effective crossing of reducing equivalents into the mitochondria, which are then used
as electron donors for the electron transport chain. Patients with Slc25a12 loss of
function mutations develop autism-like neurological abnormalities and seizures early
in life. In this study, we employ knock out (KO) mouse technology to study the effect
of complete Slc25a12 KO on different neural cell types. We show that Slc25a12 KO
hippocampal astrocytes undergo apoptosis, down-regulate their expression of
glutamate reuptake transporters, and up-regulate the neuromodulatory protein
adenosine kinase, all of which may contribute to the dysregulation of glutamatergic
neurotransmission. Our data uncover an unexpected role for astrocytes in seizure
genesis and continue to underscore the importance of studying the most abundant and
underappreciated neural cell type to probe its contributions to seizures and other
neurological disorders, as well as its potential for therapeutic interventions.
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Introduction
The mitochondrial aspartate-glutamate carrier isoform 1, also known as aralar,
or Slc25a12, is a calcium-binding protein localized to the inner mitochondrial
membrane. As part of the malate-aspartate shuttle, it transfers reducing equivalents in
the form of NADH from the cytosol to the mitochondria by catalyzing the exchange
of intermitochondrial aspartate and cytosolic glutamate and a proton (Figure 3.1).
Discovered and cloned in 1998 (del Arco and Satrústegui, 1998), Slc25a12 was later
identified as an autism susceptibility gene after multiple genome wide association
studies found Slc25a12 SNPs highly associated with autism spectrum disorders
(Ramoz et al., 2004; Segurado et al., 2005; Silverman et al., 2008; Turunen et al.,
2008; Chien et al., 2010; Kim et al., 2011; Anitha et al., 2012; Li et al., 2012;
Prandini et al., 2012). Though the link between Slc25a12 and autism has been
contested by a few (Blasi et al., 2006; Correia et al., 2006; Rabionet et al., 2006;
Lepagnol-Bestel et al., 2008), two recent meta-analysis studies further substantiated
the association (Aoki and Cortese, 2015; Liu et al., 2015). Recently, two independent
case studies identified three patients with loss of function mutations in Slc25a12
(Wibom et al., 2009; Falk et al., 2014). These patients develop normally during the
first few months of life after which they begin to develop psychomotor deficits and
seizures. It is not currently known what changes in the brain resulting from Slc25a12
loss of function lead to seizures. Here, we use Slc25a12 KO mice to investigate the
effect of Slc25a12 loss of function on different neural cell types to examine their role
in seizure genesis.
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The pathogenesis of astrocytes is increasingly being recognized as a major
contributor to many neurological disorders. In seizure disorders, a number of
astrocyte-specific deficiencies have now been identified in both human temporal lobe
and animal models of epilepsy that contribute to seizure propensity (Bordey and
Sontheimer, 1998; Das et al., 2012). The most well established astrocyte abnormality
documented in seizure disorders is reactive astrocytosis, whereby astrocytes display
hypertrophic morphology and increased expression of astrocytic intermediate
filaments GFAP and vimentin. Other astrocyte deficiencies include changes in ion
channel composition (Kir4.1) reflecting an inability of astrocytes to buffer
extracellular potassium (Wallraff et al., 2006; Sicca et al., 2011); reduction in
glutamate transporters (GLT-1, GLAST) (Mathern et al., 1999; Proper et al., 2012;
Sarac et al., 2009; Takahashi et al., 2010) and glutamate degrading enzymes such as
glutamine synthetase (Dennis et al., 1977; Eid et al., 2004; van der Hel et al., 2005),
resulting in the inability to sequester and degrade synaptic glutamate into the
astrocytic cytosol; and disrupted homeostasis of neurotransmitter precursors for both
excitatory and inhibitory neurotransmission . In this study, we report a novel
astrocytic deficiency that we believe may further contribute to the pathophysiology
and exacerbation of seizures in Slc25a12 KO mice.

Results
Slc25a12 is expressed in neurons, interneurons, and astrocytes
Slc25a12 mRNA is expressed in pyramidal neurons in mouse cortex and
hippocampus (del Arco et al., 2002; Ramos et al., 2003), prompting us to examine
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whether the regional localization of its protein expression follows suit. We probed
brain tissue from wild type mouse brain using antibodies recognizing Slc25a12. We
found that Slc25a12 protein was highly expressed in cortical pyramidal neurons
(Figure 3.2A), similar to mRNA in situ hybridization expression patterns. Here, we
also demonstrated the specificity of the Slc25a12 antibody by using it on Slc25a12
KO brain tissue, where Slc25a12 protein is clearly not detected (Figure 3.2A). To
determine whether Slc25a12 is expressed in inhibitory interneurons, we examined
wild type mouse brain tissues using antibodies against parvalbumin (PV), the
calcium-binding protein expressed in a subset of fast-spiking interneurons. Consistent
with the high numbers of mitochondria in PV interneurons (Gulyás et al., 2006), we
found that Slc25a12 protein was also detected in this cell type (Figure 3.2B).
The astrocytic expression of Slc25a12 has not been established and is highly
debated. Some groups found that astrocytes do not express Slc25a12 protein (Ramos
et al., 2003; Pardo et al., 2011), while others argued that astrocytes are metabolically
compromised without Slc25a12, and demonstrated using the rigorous methodology of
electron microscopy with immunogold labeling, that astrocytes do in fact express
Slc25a12 (Li et al., 2012). Using a GLT-1-GFP transgenic BAC mouse, which
expresses GFP in all astrocytes from P10 to adulthood (Regan et al., 2007), we found
prominent Slc25a12 expression in astrocytes of both the cortex and the hippocampus
(Figure 3.2C). This implies that Slc25a12 loss of function may have more diverse
effects than previously realized, given the intermediary roles that astrocytes have,
particularly in glutamatergic neurotransmission.
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Loss of Slc25a12 does not adversely impact interneuron development and
differentiation
Abnormal GABAergic signaling is known to underlie some seizure disorders,
as evidenced by genetic mutations in interneuron development that lead to seizure
states (McManus and Golden, 2005; Friocourt et al., 2008; Cobos et al., 2005).
Interestingly, mitochondrial disease is also starting to gain recognition as a major
contributor to seizures and epilepsy, as the incidence of seizures in patients with
mitochondrial disease is greater than that of the general population and the fact that
there is an increasing number of identified mitochondrial mutations that result in
epilepsy (Khurana et al., 2008; Kang et al., 2013). Preliminary data from our lab has
shown that interneurons rely on mitochondrial oxidative phosphorylation for
tangential migration to the cortex (Lin-Hendel et al., unpublished), further
substantiating, and establishing a precedent for the dual role that interneurons and
mitochondria play in seizure disorders. This led us to investigate whether loss of
Slc25a12 would result in a deficit in interneuron development.
We examined GABAergic interneuron numbers in wild type and Slc25a12
KO mice by probing tissues with an antibody against GABA. We focused our
analysis on the hippocampus, since it is known to be a highly epileptogenic region,
and it was previously demonstrated that loss of interneurons in the hippocampus led
to a seizure-like state (Sloviter, 1987; de Lanerolle et al., 1989; Dudek, 2002; Cobos
et al., 2005). To our surprise, the number of GABAergic interneurons in Slc25a12
KO hippocampus did not significantly differ from wild type (Figure 3.3A).
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To investigate whether Slc25a12 KO affected interneuron differentiation, we
induced interneuron differentiation on induced pluripotent stem cells (iPSCs) derived
from patients with partial Slc25a12 loss of function (Falk et al., 2014). The
differentiation protocol has been used in our lab to successfully differentiate iPSCs
into interneurons (Maroof et al., 2013) and consists of exposing iPSCs to a variety of
small molecules to first enhance forebrain differentiation and then achieve cell type
ventralization, mimicking the environment of the medial ganglionic eminence where
interneurons are naturally born (Figure 3.3B). After subjecting patient-derived iPSCs
to this differentiation protocol, we showed that Slc25a12 loss of function iPSCs were
able to successfully differentiate into cells that expressed Nkx2.1, a transcription
factor critical for the determination and specification of inhibitory interneurons
(Figure 3.3C), suggesting that Slc25a12 loss of function does not affect the initial
development of GABAergic interneurons.
Though the investigation of interneuron numbers and differentiation does not
shed light on the effect of Slc25a12 KO on interneuron function, it suggests that
Slc25a12 is not required for interneuron migration and that insufficient interneuron
numbers is most likely not the cause of seizures in Slc25a12 KO mice/patients.

Slc25a12 KO results in hippocampal selective astrocyte apoptosis with compensatory
increase in astrocyte numbers
Despite the respiratory chain being functionally intact, patients with loss of
function mutations in Slc25a12 have reduced ATP output (Wibom et al., 2009), most
likely due to a reduction in reducing equivalents (used to fuel ATP synthesis) being
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imported into the mitochondria by Slc25a12’s actions as part of the malate aspartate
shuttle. Cells that undergo metabolic stress and do not produce enough ATP can
undergo apoptosis (Aito et al., 2002; Altman and Rathmell, 2012). The brain is one of
the most energy-consuming organs in the body, using up to 20% of the body’s basal
metabolism despite being only 2% of the total body weight (Raichle and Gusnard,
2002). We reasoned that the high-energy demands of the brain would make it
particularly susceptible to reduced ATP output, leading to cellular apoptosis across
the board. To test this idea, we examined wild type and Slc25a12 KO brains with the
apoptotic marker cleaved caspase 3.
To our surprise, we observed an astounding region-specific enrichment of
cleaved caspase 3-expressing cells in the hippocampus of Slc25a12 KO mice (Figure
3.4A). Using double labeling with the astrocytic marker S100β, we also determined
that the apoptosis was specific to astrocytes, with over 50% of S100β-expressing
astrocytes also expressing apoptotic markers (Figure 3.4B). The statistical variance
observed may be due to the small number of animals tested, but quite possibly also
the heterogeneity in the developmental progression of the phenotype. This
heterogeneity is also observed in the patients with loss of function Slc25a12
mutations, where the onset of seizures varies from 7-10 months. Though we observed
apoptosis in all hippocampal CA fields, the phenotype was most pronounced and
statistically significant in the hilus, and we confirmed this result using other apoptotic
markers cleaved PARP and the TUNEL assay (Figure 3.4C).
In mouse, most astrocytes in the hippocampus are generated by P16 (NixdorfBergweiler et al., 1994). Since astrocyte apoptosis is most pronounced at P16 in
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Slc25a12 KO hippocampus, we wondered whether the putative loss of astrocytes to
apoptosis in Slc25a12 KO hippocampus would lead to a compensatory increase in
astrocytes. To test this question, we examined whether an increase in both immature
and mature astrocytes would be apparent in Slc25a12 KO hippocampus. In wild type
hippocampus, the immature astrocyte marker CD44 is expressed at low levels from
P5-P7 and diminishes at P11, consistent with the developmental timeline of astrocyte
proliferation (Bushong et al., 2004). In Slc25a12 KO hippocampus, CD44 was
enriched from P5-P7, and particularly at P11 (Figure 3.5A), indicating either that
astrocyte maturation is delayed, or that astrocytes proliferate to replenish apoptosing
astrocytes. An analysis of total astrocyte numbers in Slc25a12 KO hippocampus at
P16 indicates that there are significantly more astrocytes compared to wild type,
suggesting that astrocyte proliferation may in fact be compensating for apoptotic cell
loss (Figure 3.5B).

Hippocampal astrocyte apoptosis is not apparent in mice deficient in the
transcription factor Arx
It had been previously demonstrated that kainic acid-induced status
epilepticus resulted in robust cleaved caspase 3 expression in astrocytes (Narkilahti et
al., 2003), suggestive of apoptosis. However, evidence for this occurring in a genetic
seizure model other than Slc25a12 KO has been lacking. To determine whether
astrocyte apoptosis could also result from non-chemically-induced persistent seizures,
we examined Arx null mice for evidence of astrocyte apoptosis.
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Arx is one of several homeodomain-containing transcription factors involved
in GABAergic interneuron migration and maturation in the brain (McManus and
Golden, 2005; Friocourt et al., 2008). Similar to patients with Slc25a12 loss of
function mutations, patients with mutations in Arx exhibit spontaneous persistent
seizures with developmental delay. Using mice with a GCG triplet repeat expansion
in Arx (Arx(GCG)10+7), which are viable and recapitulates the features of the human
triplet repeat expansion (Price et al., 2009), we observed that astrocyte apoptosis was
not apparent before or after the age of seizure onset (~P30) (Figure 3.6), suggesting
that the phenotype is unique to Slc25a12 KO.

Hippocampal astrocyte apoptosis precedes onset of behavioral seizures
In many epilepsy models as well as in human epilepsy, prolonged seizures can
result in neuronal cell death in the hippocampus (Zhang et al., 1998; Faherty et al.,
1999; Henshall et al., 2004; Henshall 2007). In one study, kainic acid-induced status
epilepticus also resulted in pronounced hippocampal astrocytic cell death (Narkilahti
et al., 2003). To determine whether astrocyte cell death in Slc25a12 KO mice
precedes seizures or is a result of them, we used video seizure monitoring to examine
whether the onset of behavioral seizures precedes or follows the onset of astrocyte
apoptosis at P11.
While behavioral seizures in Slc25a12 KO mice are entirely spontaneous, we
found that a one-hour period of monitoring from ages P7-P16 was sufficient to
document a spontaneous seizure. In this time period, 6 of 7 Slc25a12 KO mice
exhibited behavioral seizures by P15, with the earliest occurring on P13, two days
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after the onset of astrocyte apoptosis (Figure 3.5C). Unlike the kainic acid-induced
seizure model where seizures resulted in astrocyte apoptosis, that astrocyte apoptosis
in Slc25a12 KO precedes the onset of behavioral seizures suggests that astrocytes
may contribute to seizure genesis.

Slc25a12 KO astrocytes down-regulate expression of glutamate transporters GLT-1
and GLAST
Astrocytes play an important role in the modulation of excitatory
neurotransmission. They achieve this in part through the expression of the sodiumdependent glutamate reuptake transporters GLT-1 and GLAST, which clear glutamate
from the synaptic cleft, thereby ceasing its effects on postsynaptic glutamate
receptors. Our evidence refuting the notion that interneurons may be a driver of
seizure genesis in Slc25a12 KO mice prompted us to examine whether Slc25a12 KO
astrocytes exhibit other abnormalities that would contribute to seizures. Previous
studies have shown that GLT-1 and GLAST protein expression is down-regulated in
other seizure models (Miller et al., 1997; Tanaka et al., 1997; Dutuit et al., 2002;
Zhang et al., 2004). To test this idea, we examined hippocampal glutamate levels and
GLT-1 and GLAST protein expression from wild type and Slc25a12 KO mice.
Our findings indicate that the expression of astrocytic glutamate reuptake
transporter GLT-1 is significantly decreased in the Slc25a12 KO hippocampus
(Figure 3.7). 5-10% of GLT-1 protein is also expressed in neurons. We maintain that
the loss of GLT-1 in Slc25a12 occurs in astrocytes, as a preliminary analysis of
glutamate reuptake in P2 synaptosomes revealed that glutamate reuptake was not
69

different between Slc25a12 KO and wild type, an effect that can be explained by the
recent finding that neuronal GLT-1 is the major contributor to glutamate uptake in P2
synaptosomes (Petr et al., 2015). Hippocampal GLAST was also shown to have a
decreasing trend (Figure 3.7). The lack of glutamate reuptake transporters in
Slc25a12 KO suggests a role for altered glutamate neurotransmission in seizure
genesis.

Electrophysiology of Slc25a12 KO pyramidal cells indicate evidence of synaptic
glutamate retention
We examined amplitude, frequency, area, and decay of mEPSPs in
hippocampal CA3 excitatory pyramidal cells in wild type and Slc25a12 KO mice. We
found the amplitude unchanged, suggesting that the amount of glutamate packaged
and released by the pyramidal cells is not different between KO and wild types
(Figure 3.8A). In addition to this, we found that there were more frequent glutamate
release events in the KO, as evidenced by the leftward shift in the cumulative
probability of Slc25a12 KO events, or the decrease in Slc25a12 KO inter-event
interval (Figure 3.8B). This finding, coupled with the enhanced area under the
mEPSP curve (Figure 3.8C) and longer delay towards signal decay (Figure 3.8D) in
Slc25a12 KO animals supports the hypothesis that Slc25a12 KO animals have
prolonged synaptic glutamate retention that may contribute to seizures. These
electrophysiological data support the biochemical GLT-1 expression data. The
glutamate reuptake transporters contribute directly to the amplitude of the mEPSPs by
virtue of their kinetics. Glutamate reuptake transporter kinetics are known to be
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considerably faster than the kinetics of post-synaptic glutamate receptors, and thus,
their absence or down-regulation will cause an enhancement of the mEPSP
amplitude. To determine how GABAergic neurotransmission is altered, we have
measured mIPSPs; the analysis is forthcoming.

Slc25a12 KO astrocytes up-regulate expression of the neuromodulatory kinase ADK
Adenosine has been identified as an inhibitory neuromodulator through its
effects on reducing glutamate release (Corradetti et al., 1984). Adenosine-modulated
inhibitory tone can be disturbed, resulting in seizure states, through its
phosphorylation into AMP by ADK. ADK exists in a long and short isoform, found in
the nucleus and cytoplasm, respectively (Cui et al., 2009). In early postnatal
development, ADK-L is expressed specifically in neuronal nuclei, and for reasons
unknown, the ADK shifts its isoform and cellular expression to astrocytic ADK-S by
P14 (Studer et al., 2006). Research from Detlev Boison’s group has shown that ADKS is up-regulated in hippocampal astrocytes in human temporal lobe epilepsy, and
becomes up-regulated as a result of reactive astrocytosis in animal models of epilepsy
(Gouder et al., 2004; Fedele et al., 2005; Li et al., 2008; Shen et al., 2014). Moreover,
overexpressing ADK-S in a kainic acid model of epilepsy exacerbated seizures,
suggesting that up-regulated ADK may play a role not only in genesis, but also in
perseverance of seizures (Fedele et al., 2005). This prompted us to examine whether
ADK was up-regulated in Slc25a12 KO mice, and whether seizures resulted from
ADK-driven loss of inhibitory tone.
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Our immunohistological examination of ADK revealed enhanced astrocytic
ADK in Slc25a12 KO hippocampus (Figure 3.9A). However, unlike previously
published reports on ADK expression levels in seizure models, we found that total
ADK protein levels were unchanged between wild type and Slc25a12 KO (Figure
3.9B). Upon further examination, we observed that ADK in Slc25a12 KO astrocytes
was localized to the nucleus. It is not known how ADK functions in the nucleus, and
whether it affects the bioavailability of adenosine like cytoplasmic ADK. However,
the aberrant localization of ADK in Slc25a12 KO astrocytes contributes to growing
evidence of astrocytic abnormalities that may contribute to altered glutamate
neurotransmission and seizure states.

Discussion
In this study, we identify a novel phenotype – hippocampal-specific astrocyte
apoptosis occurring before the onset of behavioral seizures – that strongly implicates
the astrocyte as a major contributor to seizure genesis in Slc25a12 KO mice. We
further confirm the role of astrocytes in Slc25a12 KO seizure genesis by showing that
astrocytes also down-regulate their expression of glutamate reuptake transporters
GLT-1 and GLAST, and up-regulate the expression of ADK, resulting in glutamate
excitotoxicity through glutamate retention in the synaptic cleft and an increase in
glutamate release events, respectively. These effects are supported by the
electrophysiological characteristics of hippocampal pyramidal cells.

Normal interneuron development in Slc25a12 KO mice
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Mitochondrial ATP via oxidative phosphorylation is required for interneuron
tangential migration (Lin-Hendel et al., unpublished), and interneurons, particularly
the fast-spiking subset, contain large amounts of mitochondria (Gulyás et al., 2006).
How might knocking out Slc25a12, a mitochondrial protein indirectly involved in
ATP generation, lead to the normal development of interneurons? Postnatal
expression of Slc25a12 is limited to only a few organs: the brain, heart, and skeletal
muscle (del Arco et al., 2002). During development, Slc25a12 shares overlapping
expression with its protein isoform Slc25a13, particularly in the brain (del Arco et al.,
2002). This overlapping expression persists until the end of neurogenesis and
interneuron migration, and suggests that Slc25a13 may provide functional
compensation for neural development in Slc25a12 KO mice, leading to normal
interneuron development.

Astrocyte apoptosis: Cell autonomy
Oligodendrocytes do not express Slc25a12, yet both Slc25a12 loss of function
patients and Slc25a12 KO mice exhibit global central nervous system
hypomyelination (Jalil et al., 2005; Wibom et al., 2009; Sakurai et al., 2009; Falk et
al., 2014), a non-cell autonomous phenotype that was demonstrated to be a result of a
lack of neuron-supplied N-acetylaspartate, which oligodendrocytes use to synthesize
myelin. The astrocytic expression of Slc25a12 has been a subject of debate. We have
shown that Slc25a12 is expressed in astrocytes, suggesting that global Slc25a12 KO
may contribute to cell autonomous effects in astrocytes, though this does not rule out
non-cell autonomous effects neuronal Slc25a12 KO may have on astrocytes.
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One method we plan to use to determine cell autonomy is an in vitro system
where neurons and astrocytes that are either both wild type, both Slc25a12 KO, or of
mixed genotypes are co-cultured. These cultures can thereafter be assayed for
astrocyte cell death. However, it is known that astrocytes in vitro substantially differ
from their in vivo counterparts. To resolve this difference, we also plan to examine
cell autonomy in vivo by transplanting doubly transgenic Slc25a12 KO; GLT-1-GFP
astrocytes into wild type, neonatal mouse pups.
Despite the issue of cell autonomy, we have so far failed to observe Slc25a12
KO astrocyte cell death in vitro using both mixed primary neuron and astrocyte
cultures and astrocyte only cultures. Moreover, it is not known whether the astrocytes
of patients with Slc25a12 loss of function mutations also exhibit cellular apoptosis.
The creation of an in vitro system that recapitulates in vivo Slc25a12 KO astrocyte
apoptosis will be essential for identifying metabolic abnormalities that may contribute
to cell death and for testing small molecules or other therapeutics for their effects on
preventing cell death. The lack of astrocyte cell death in vitro may be attributed to
known differences between cultured and in vivo astrocytes, or the high availability of
glucose and additional glycolytic substrates in the culture media. Future experiments
include culturing Slc25a12 KO astrocytes in low glucose, low oxygen conditions,
both of which have been demonstrated to have effects on astrocyte survival (Paquet et
al., 2013).

Astrocyte apoptosis: Patient profile
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Astrocytic abnormalities have not been reported in patients with Slc25a12 loss
of function mutations, and it is not known whether astrocytes from these patients
undergo apoptosis. We tested this question by generating astrocytes from patientderived iPSCs and transplanting them into wild type (NOD-SCID) neonatal mouse
cortex. Our preliminary experiments suggest that patient astrocytes do not undergo
apoptosis, even after 3 weeks in vivo. However, it has been well documented that
human astrocytes have uniquely hominid features that differentiate them from those
of other mammals (Oberheim et al., 2009). These features include enhanced
morphological complexity resulting in overlapping patterning, phenotypic diversity of
GFAP expression, as well the existence of novel astrocyte population, which may
contribute to or account for the phenotypic discrepancy observed between patient and
Slc25a12 KO astrocytes. The discrepancy also seems to suggest that astrocyte cell
death may be a cell non-autonomous effect, since the genotypic in vivo
microenvironment patient astrocytes were transplanted in was wild type. We plan to
use Slc25a12 KO mice as transplant recipients in future experiments to further
explore this question.
Another possible reason for the survival of patient astrocytes in vivo is the
difference in Slc25a12 protein functionality between patients and the knockout
mouse. Unlike the mouse model, which by virtue of being a protein knockout, results
in 0% protein functionality, the patients (from whom the iPSCs used in this study
were generated) harbor mutations that confer only a partial loss of function that
results in 15% protein functionality compared to wild type Slc25a12. It is possible
that the retention of some, albeit limited, protein functionality is able to sustain
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astrocyte metabolism enough to promote cell survival. A separate case study
identified patients with a different mutation in Slc25a12 that conferred 0% protein
functionality (Wibom et al., 2009). Future studies using derived astrocytes from these
patients may be able to shed light on this issue.
Finally, an important caveat to consider is the heterogeneity of astrocytes; a
multitude of different astrocyte cell types have been identified that differ with respect
to their morphologies, localization, and transcriptomes (Matyash and Kettenmann,
2010; Chaboub and Deneen, 2012; Zhang et al., 2014). Using a previously published
differentiation protocol (Krencik et al., 2011), we were able to differentiate patientderived iPSCs into cells that expressed glutamine synthetase and GFAP (not shown).
However, the current state of not only identification of astrocytic subtypes, but also
methods for their differentiation from iPSCs is not as advanced as it is for neurons,
for which there are published subtype specific markers and protocols for
differentiation into excitatory, motor, and even inhibitory neuron subtypes with fine
specificity. Though the cells we generated were astrocytic in nature, it is unclear what
type of astrocyte was generated. Upon transplantation, patient astrocytes did not
demonstrate localization specificity. Rather, they migrated to every brain region,
consistent with previous published reports on human astrocyte transplants (Windrem
et al., 2014). The vast heterogeneity of astrocytes and the current challenge of
differentiating subtype specific astrocytes from iPSCs must be kept in mind in the
interpretation of these experiments.

Concluding Remarks
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In healthy individuals, mitochondria function optimally to provide energy to
sustain the metabolic needs of all cell types. In the brain, mitochondria are especially
important as the brain uses 20% of the body’s basal metabolism. Thus, it is not
surprising that encephalomyopathy is the most common symptom of mitochondrial
disease. The diversity of mitochondrial diseases yields heterogeneity in the resulting
encephalomyopathies. The first step in therapeutic development for seizures resulting
from mitochondrial disease is identifying and understanding changes in the
development and function of neural cell types. To this end, the findings described in
this Chapter provide novel insight on astrocytic contributions to dysregulated
glutamatergic neurotransmission and seizures in a particular mitochondrial disease
resulting from Slc25a12 loss of function. In addition, this work underscores the
importance of studying astrocytes in disease and suggests that cell-targeted
therapeutics may be a beneficial avenue to explore in treating this disease.
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Experimental Procedures
Animals
Slc25a12 heterozygous mice were re-derived from sperm (a gift from the
Joseph Buxbaum lab) and out-bred once onto a CD1 genetic background.
Heterozygous mice were bred with each other to generate homozygous Slc25a12 KO
mice, which were viable until approximately P22 and born in expected Mendelian
ratios. For preparation of brain tissue, animals were transcardially perfused with
phosphate buffer saline (PBS) followed by 4% paraformaldehyde (PFA). Brains were
removed from the skull, immersed in 4% PFA overnight, washed three times with
PBS at room temperature. Brains were then mounted in 4% low-melt agarose and
sectioned at 50 µm using a Leica vibratome. All experiments described in this study
were performed in accordance with an approved institutional animal care and use
committee protocol.

Immunohistochemistry
Brain sections were blocked for 1 hour at room temperature (5% BSA in 0.1%
PBS-Triton) and probed in blocking buffer with antibodies recognizing Slc25a12
(Thermo Scientific, PA5-23778, 1:100), PV (Swant, PV 235, 1:2500), GFP (Abcam,
ab13970, 1:1000), GABA (Swant, GABA 3A12, 1:500), S100β (Sigma, S2657,
1:100), cleaved caspase 3 (Cell Signaling, 9664S, 1:400), cleaved PARP (Cell
Signaling, 9544S, 1:400), CD44 (BD Biosciences, 550538, 1:50), or ADK (gift from
Boison Detlev, 1:500) overnight at 4°C. The following secondary antibodies were
used: Alexa-568 goat anti-rabbit (Life Technologies, A-11011, 1:1000), Alexa-488
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goat anti-mouse (Life Technologies, A-11001, 1:1000), Alexa-488 goat anti-chicken
(Life Technologies, A-11039, 1:1000), Alexa-568 goat anti-mouse (Life
Technologies, A-11034, 1:1000).
For differentiated patient-derived iPSCs, cells were fixed for 20 minutes at
room temperature with 4% PFA, washed three times with PBS, blocked blocked for 1
hour at room temperature (5% BSA in 0.1% PBS-Triton) and probed in blocking
buffer with an antibody recognizing Nkx2.1 (Abcam, ab72876, 1:100). The secondary
antibody used was Alexa-568 goat anti-rabbit (Life Technologies, A-11011, 1:1000).

TUNEL assay
Floating 50 µm sections were treated with 50 µl of 10 µg/ml Proteinase K in
10 mM Tris-HCl, pH 7.5 for 5 minutes at 37°C, washed three times in PBS, and then
incubated in In Situ Cell Death Detection Kit TUNEL reaction mixture (Roche,
11684795910) according to the manufacturer’s instructions. Positive controls were
achieved by incubating wild type sections in 3000 U/ml DNase I recombinant (Roche
4716728001) in 50 mM Tris-HCl, pH 7.5, 1 mg/ml BSA for 10 minutes at room
temperature.

Imaging and phenotypic analysis
Images were acquired using a Photometrics CoolSNAP ES2 camera attached
to a Nikon Eclipse Ni microscope with NIS Elements AR imaging software. Images
were processed using Adobe Photoshop and scored using ImageJ Cell Counter tool.
When counting cells, a cell was considered to be apoptotic or GABAergic if the
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fluorescent signal was pervasive throughout the cell body or nucleus (representing
cells on the top plane of the tissue), with nuclear DAPI present. Cells were counted
only in the hippocampal hilus and did not extend to the region beyond the fork of the
dentate gyrus. For pixel area quantification in CD44 experiment, thresholding was
achieved by first calculating the mean and standard deviation (σ) for three randomly
selected background staining ROIs. Three times the standard deviation above the
mean was established as the positive detection threshold.

Patient-derived iPSC interneuron differentiation
Patient-derived iPSCs were maintained on 5% extracellular matrix (Sigma,
E6909) in DMEM/F-12 media until confluency. Once confluent, cells were re-plated
into ECM-coated 24-well plates for differentiation. For differentiation, iPSCs were
treated with KnockOut Serum Replacement media (Life Technologies, 10828-028)
supplemented with LDN-193189 (Stemgent, 04-0074, 100 nM), SB431542
(Stemgent, 04-0010, 10 µM), and XAV939 (Stemgent, 04-00046, 2 µM), hereafter
referred to as “LSX” media, from differentiation days (Zhang et al.) 0-4. From DD45, iPSCs were treated with 3:1 LSX:N2 media (N2 media consists of DMEM/F-12
with 0.75 g D-glucose (EM Science, DX0156), 1% glutamax (Gibco, 35050), 1% N2
supplement B (Stemgent, 07156), 0.1% beta-mercaptoethanol (Life Technologies,
21985-023), and 0.2% primocin (Life Technologies, Ant-pm-2)). From DD6-7, iPSCs
were treated with 1:1 LSX:N2 media, and from DD8-9, with 1:3 LSX:N2 media.
From DD10-18, iPSCs were subject to ventral cell patterning by being treated with
N2+B27 media containing human Shh (R&D, 1845-SH-0251, 100 ng/mL) and
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purmorphamine (Stemgent, 04-009, 1 µM). From DD18 onwards, iPSCs were treated
with Neurobasal media (Gibco, 21103) with B27 supplement (Life Technologies,
17504).

Video behavioral seizure monitoring
P7 to P16 age Slc25a12 KO mice and wild type littermates were placed in
cage compartment on top of a heated pad for 1 hour. Behavioral seizures were
recorded with a digital video camera (Stellate Systems; Harmonie, version 5.0b).

Western assay
To generate hippocampal protein lysates, brains were quickly dissected on dry
ice and hippocampus was isolated from the overlying cortex. Tissues were placed in
pre-weighed Eppendorf tubes, and 1 ml RIPA lysis buffer with protease inhibitor
(Sigma, P8340, 1:100) was added per 200 mg tissue. Tissues were homogenized
using a handheld tissue homogenizer, agitated for 2 hours at 4°C, then centrifuged at
12,000 RPM for 20 minutes. 5, 10, and 40 µg protein for the detection of GLT-1,
GLAST, and ADK respectively, were loaded into 4-12% Bis-Tris Plus Gels (Life
Technologies, BG04120BOX), electrophoresed for 40-60 minutes at 80V, then
transferred onto nitrocellulose membranes using the iBlot dry blotting system (Life
Technologies, IB1001). Membranes were incubated for 1 hour at room temperature in
Odyssey blocking buffer (Licor, 927-50000), washed three times in PBS with 0.1%
Tween (PBS-T), then incubated overnight at 4° in with antibodies recognizing GLT-1
(Jeffrey Rothstein lab, 1:5000), GLAST (Miltenyi Biotec, 130-095-822, 1:50), and
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ADK (Detlev Boisson lab, 1:6000). After washing membranes three times with PBST, membranes were incubated with Licor Odyssey secondary antibodies according to
the manufacturer’s instructions, and developed and quantified using the Odyssey CLx
Infrared Imaging System (Licor) and Image Studio Lite software (Licor).

Electrophysiology
Mice aged P13-P17 were anesthetized with isoflurane and decapitated. Brains
were dissected out placed immediately in bubbled ice cutting solution (2.5 mM KCl,
1.25 mM NaH2PO4, 218 mM sucrose, 26 mM NaHCO3, 10 mM D-glucose, 0.5 mM
CaCl2, 10 mM MgSO4, with 95% O2 and 5% CO2 and 285 mOsM). Brains were
bisected down the midline and mounted on a cutting stage angled at 12-15 degrees to
produce 350 µm thick hippocampal entorhinal cortex sagittal slices. Slices were
placed in bubbled artificial cerebrospinal fluid (130 mM NaCl, 2.75 mM KCl, 1.1
mM NaH2PO4, 28.82 mM NaHCO3, 11.1 mM D-glucose, 2.5 mM CaCl2, 1.43 mM
MgSO4 with 315 mOsM) for 30 minutes at 37°C, then at room temperature for 1 hour
prior to recording. For mEPSC and sIPSP recordings, pyramidal cells in CA3 were
patched with an internal pipette solution consisting of 5 mM KCl, 135 mM Kgluconate, 2 mM NaCl, 10 mM HEPES, 4 mM EGTA, 4 mM MgATP, 0.3 mM
Na3GTP, with a pH of 7.2 and osmolarity of 285 mOsM. Cells were held at -60 mV
in the presence of 0.5 µM tetrodotoxin (mEPSC) and -40 mV (sIPSP). After
recording, cells were filled with neurobiotin (Vector Labs, SP-1120) for postrecording processing.

82

ADK inhibitor treatment
ABT-702 (Tocris, 2372) was reconstituted in sterile DMSO. Mice will be
given daily intraperitoneal injections of 10 mg/kg ABT-702 in sterile PBS (Tocris,
2372) from P10-P16, 12 hours before prior to the assessment of behavioral seizures
by video monitoring.
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Figure 3.1. Slc25a12 (AGC) is localized to the inner mitochondrial membrane
where it is a part of the malate aspartate shuttle.
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Figure 3.1. Slc25a12 (AGC) is localized to the inner mitochondrial membrane
where it is a part of the malate aspartate shuttle.
As part of the malate-aspartate shuttle with the oxoglutarate carrier (OGC), Slc25a12
(shown here as AGC) catalyzes the exchange of intramitochondrial aspartate and
cytosolic glutamate plus a proton. This process brings NADH from the cytosol to the
mitochondria, where its electrons participate in the electron transport chain to
generate ATP for the cell.
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Figure 3.2. Slc25a12 is expressed in neurons, interneurons, and astrocytes
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Figure 3.2. Slc25a12 is expressed in neurons, interneurons, and astrocytes
A) Fluorescence immunohistochemistry for Slc25a12 (red) in P16 wild type (left)
and Slc25a12 KO (right) mouse cortex. Dorsal is up.
B) Fluorescence immunohistochemistry for Slc25a12 (red) and parvalbumin (green)
in P16 wild type mouse brain. Open arrowhead indicates cells that co-express
Slc25a12 and parvalbumin. Closed arrowheads show cells that express only
Slc25a12.
C) Fluorescence immunohistochemistry for Slc25a12 (red) and GFP (green, driven
by GLT-1/BAC). Open arrowhead indicates cells that co-express Slc25a12 and
GFP. Closed arrowheads show cells that express only Slc25a12.
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Figure 3.3. Loss of Slc25a12 does not adversely impact interneuron development
and differentiation

88

Figure 3.3. Loss of Slc25a12 does not adversely impact interneuron development
and differentiation
A) Fluorescence immunohistochemistry for GABA (red) and DAPI (blue) of P11
wild type and Slc25a12 KO hippocampus (left). Quantification of GABA cell
counts (right). Data were analyzed by two-tailed Student’s t-test. Error bars
indicate SEM.
B) Patient-derived induced pluripotent stem cell protocol for differentiation into
putative interneurons.
C) Fluorescence immunocytochemistry for the putative interneuron marker Nkx2.1
(red) and DAPI (blue) on Slc25a12 loss of function patient-derived induced
pluripotent stem cells differentiated into ventralized, putative interneurons after
40 days of differentiation.
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Figure 3.4. Slc25a12 KO results in hippocampal selective astrocyte apoptosis.
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Figure 3.4. Slc25a12 KO results in hippocampal selective astrocyte apoptosis.
A) Fluorescence immunohistochemistry for the apoptotic marker cleaved caspase 3
(red) and S100β (green) in P16 wild type (top panel) and Slc25a12 KO (bottom
panel) hippocampus. DG indicates dentate gyrus.
B) Quantification of the astrocytes expressing apoptotic markers cleaved caspase 3
or cleaved PARP. Data were analyzed by two-tailed Student’s t-test. * indicates
p<0.05 compared to wild type. Error bars indicate SEM.
C) Fluorescence immunohistochemistry for the apoptotic marker cleaved PARP
(red), on left, and fluorescein-conjugated TUNEL reaction (green), on right.
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Figure 3.5. Astrocyte apoptosis is accompanied by compensatory increase in
astrocyte numbers and precedes the onset of behavioral seizures.
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Figure 3.5. Astrocyte apoptosis is accompanied by compensatory increase in
astrocyte numbers and precedes the onset of behavioral seizures.
A) Inverted image of fluorescence immunohistochemistry for CD44 (dark) in P11
wild type and Slc25a12 KO hippocampus (left). Quantification of pixel area
(right). Thresholding for CD44 signal was achieved by first calculating the mean
and standard deviation (σ) for three randomly selected background staining ROIs.
Three times the standard deviation above the mean became the positive detection
threshold. DG indicates dentate gyrus. Data were analyzed using two-tailed
Student’s t-test. * indicates p<0.05. Error bars indicate SEM.
B) Quantification of hippocampal astrocyte number at P11 (blue) and P16 (red).
Solid bars indicate wild type, and hatched bars indicate Slc25a12 KO. Data wre
analyzed using two-tailed Student’s t-test. * indicates p<0.05. Error bars indicate
SEM.
C) Line chart illustrating time of onset for astrocyte apoptosis and behavioral
seizures in wild type and Slc25a12 KO mice.
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Figure 3.6. Hippocampal astrocyte apoptosis is not apparent in mice deficient in
the transcription factor Arx.
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Figure 3.6. Hippocampal astrocyte apoptosis is not apparent in mice deficient in
the transcription factor Arx.
Fluorescence immunohistochemistry for the apoptotic marker cleaved caspase 3 (red)
and S100β (green) in P16 Arx(GCG)10+7 mice (n=2).
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Figure 3.7. Slc25a12 KO astrocytes down-regulate expression of glutamate
transporters GLT-1 and GLAST.
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Figure 3.7. Slc25a12 KO astrocytes down-regulate expression of glutamate
transporters GLT-1 and GLAST.
Representative blots for GLT-1 and GLAST are shown on the left panel.
Quantification of blot intensity on right. Data were analyzed with two-tailed Student’s
t-test. * indicates p<0.05. Error bars indicate SEM.
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Figure 3.8. Electrophysiology of Slc25a12 KO pyramidal cells indicate evidence
of synaptic glutamate retention.
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Figure 3.8. Electrophysiology of Slc25a12 KO pyramidal cells indicate evidence
of synaptic glutamate retention.
A) Histogram depicting the number of events for a bin of amplitudes for wild type
(green) and Slc25a12 KO (blue) on left, followed by cumulative probability K-S
curve for amplitude, on right.
B) Inter-event interval cumulative probability K-S curve for wild type (green) and
Slc25a12 KO (green).
C) Histogram depicting the number of events for a bin of mEPSP areas for wild type
(green) and Slc25a12 KO (blue) on left, followed by cumulative probability K-S
curve for mEPSP area, on right.
D) mEPSP decay cumulative probability K-S curve for wild type (green) and
Slc25a12 KO (green).
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Figure 3.9. Slc25a12 KO astrocytes up-regulate expression of the
neuromodulatory kinase ADK.

B
ADK
βactin

WT

KO
43

100

Figure 3.9. Slc25a12 KO astrocytes up-regulate expression of the
neuromodulatory kinase ADK.
A) Fluorescence immunohistochemistry for ADK (red) in hippocampus of P16 wild
type and Slc25a12 KO mice. SR, SLM, SM, DG indicate stratum radiatum,
stratum lacunosum moleculare, stratum moleculare, and dentate gyrus
respectively.
B) Representative blots for ADK are shown on the top panel. Band intensity was
quantified for both long and short isoforms, and was not significantly different
between wild type and KO. The quantification of total band intensity is shown on
the bottom panel. Data were analyzed with two-tailed Student’s t-test. Error bars
indicate SEM.
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Chapter 4
Future Directions
The first part of my thesis research found an unprecedented association
between the human papillomavirus type 16 oncoprotein E6 and human focal cortical
dysplasia type IIB (FCDIIB) through the detection of E6 DNA, mRNA, and protein
in FCDIIB brain specimens that is not detected in controls. Additionally, my research
established a functional link between E6 expression and the development of cortical
malformations in an acute mouse model of focal cortical malformations. Several
questions on how HPV can infect the brain remain unanswered, including the mode
of HPV transmission to the brain and the putative unique tropism of HPV for
epithelial cells. In addition, my thesis work raised several broader questions,
including whether these findings are reproducible and what they mean for the general
population and the incidence of epilepsy and HPV.
The second part of my research uncovered a novel, hippocampal astrocyte
apoptosis phenotype accompanied by increased astrocyte turnover, down-regulation
of the glutamate reuptake transporter GLT-1, and up-regulation of adenosine kinase,
resulting from Slc25a12 knockout. Because of the role astrocytes play in modulating
excitatory glutamatergic neurotransmission, these findings suggest that excitotoxic
glutamatergic neurotransmission preceded by astrocyte abnormalities is the root of
seizures in the Slc25a12 KO mouse model. This work raises interesting questions
about developmental and compensatory astrocyte homeostasis, such as whether
astrocyte maturation is delayed and whether the astrocytic expression of apoptotic
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markers is a definitive indicator of cellular apoptosis. In this chapter, I will discuss
experimental approaches to answer these questions.
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Part 1
HPV mode of transmission
Because it is believed that FCDIIB forms during embryonic brain
development, the question of how HPV infection is acquired or transmitted remains.
One highly appealing possibility is transplacental HPV16 infection of neuroglial
progenitor cells in utero during brain development. The transplacental HPV
transmission rate has been reported as 12.2% (Rombaldi et al., 2008), and as the
prevalence of HPV infection is estimated at 26.8% (Dunne et al., 2007) in the United
States, transplacental transmission of HPV16 is a plausible mechanism for entry into
the brain (Figure 4.1). Alternatively, it is conceivable that the effects of HPV16 E6
could lead to FCDIIB formation in the early neonatal period.
Unfortunately, there is no easy experimental model to validate transplacental
transmission. In vitro models, such as the mouse vaginal challenge model, are
insufficient since real human papillomaviruses are dangerous to work with and not
readily isolatable. One possibility is to conduct a retrospective correlational study on
the HPV status of the parents of FCDIIB patients. However, this would be speculative
at best, since there is no effective means of knowing whether a parent was infected
with HPV before or after the birth of an FCDIIB patient. Since the advent of the HPV
vaccine, prospective studies on the incidence of FCDIIB are now possible.

The tropism of human papillomavirus: Can HPV infect the brain?
Human papillomavirus type 16 is widely known as the virus that causes
cervical cancer, and it is generally believed that HPV displays unique tropism for
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epithelial cells. However, recent research has yielded an increasing body of evidence
indicating that this may not be this case. HPV has been detected in peripheral nerves
adjacent to oropharyngeal cancers and in spermatozoa (Füle et al., 2006; Foresta et
al., 2011). Additionally, the detection of HPV genomic elements and oncoproteins in
human FCDIIB brain provides further evidence for the widespread tropism of HPV.
HPV infection has been demonstrated in vitro and in vivo to occur through the
binding of viral capsid protein L1 to cell surface HSPGs (Giroglou et al., 2001;
Horvath et al., 2010; Schiller et al., 2010). Additional studies have specified
syndecan-1 as the critical HSPG needed for HPV binding and infection (ShaftiKeramat et al., 2003; Knappe et al., 2007). Syndecan-1, a type I transmembrane
HSPG and a member of the syndecan proteoglycan family is highly expressed in
neuroglial progenitor cells in the ventricular zone of the developing brain, but not in
mature neurons (Nakanishi et al., 1997), suggesting that neuroglial progenitor cells
may be susceptible to infection by HPV during development.
One experiment that can answer the question of whether neuroglial progenitor
cells can be infected by HPV is to culture murine neuroglial progenitor cells
(mNPCs) with HPV pseudoviruses. Pseudoviruses are commonly used in HPV
research as they do not contain viral genomes and are considered biologically safe
reagents. They are generated by introducing two plasmids into 293TT cells: one
encoding both viral capsid proteins L1 and L2; and the other, which serves as the
viral “pseudogenome,” encoding E6-GFP under the control of the SV40 origin of
replication. Viral capsid proteins assemble in vitro and encapsulate the
pseudogenome. The resultant pseudoviruses can then be extracted by detergent lysis
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and purified using density gradient ultracentrifugation.
mNPC infectability can be assayed by co-culturing with HPV pseudoviruses.
Infection is achieved when the pseudogenome containing GFP is transmitted to the
host cell. The necessity of syndecan-1 for HPV pseudovirus infection can be tested by
stably knocking down syndecan-1 in mNPCs and assaying for infection. The ability
of syndecan-1 to facilitate HPV pseudovirus infection on its own can also be tested by
transiently transfecting syndecan-1 into K562 cells (which do not normally express
syndecan-1).
It is possible that L1 may bind syndecan-1, but mNPCs may not be infected.
As pseudoviruses have been demonstrated to be agents of infection in other cell types
that express syndecan-1, this suggests that perhaps other proteins may be involved in
facilitating pseudovirus infection that may not be expressed in mNPCs, but may be
expressed in cells of an earlier developmental time point, such as neural stem cells.
Additionally, L1 may not bind syndecan-1, but mNPCs may become infected.
However, given that the dissociation constant of L1 to heparan sulfate groups is in the
range of 10-5-10-7 M in vitro (Sun et al., 2010), the possibility that L1 will not bind
syndecan-1 is very low. However, if there is no binding, it would suggest that HPV
pseudoviruses use other proteins to facilitate infection in mNPCs and that the
mechanism of HPV infection in neural cell types is unique and different from that
which governs epithelial cells.
Lastly, L1 may not bind syndecan-1 in any neural cell type suggesting that
there may be species-specific interactions inhibiting HPV pseudovirus binding and
infection or neural cell types are unable to be infected by HPV. In the case of the
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former, a reasonable follow-up experiment would be to test HPV pseudovirus
infectability in human neuroglial progenitor cells, which are commercially available.
In the case of the latter, it is possible that HPV can enter the brain by virtue of
somatic genome integration when an infected sperm fertilizes an oocyte.

Reproducibility of results
Since the publication of the data in Chapter 2, three independent groups have
repeated this study to varying results. The first of these published reports, published
in 2014 (Liu et al., 2014), conducted PCR and immunohistochemistry for HPV on 27
FCDIIA and 20 FCDIIB specimens. Their data indicate that HPV16 was detected in
90% of FCDIIB and 22.2% of FCDIIA specimens. My thesis research indicated that
HPV16 E6 was present in balloon cells of FCDIIB, making its detection in FCDIIA, a
focal malformation disorder without balloon cells, an interesting finding. In addition
to detecting HPV, Liu and colleagues also detected four other common intrauterine
infection-related viruses – cytomegalovirus (19.1%), human herpes virus-6B (12.7%),
and herpes simplex virus-1 (31.9%) in non-specified FCD specimens. Of 36 normal
brain specimens examined, only 2 were positive for viral expression (not specified).
While their data support the findings of Chapter 2, the discovery of additional viruses
in FCD specimens detracts from the hypothesized causal association between HPV
and FCDIIB, as it is not known how the other viruses affect mTOR signaling and
brain development. Cytomegalovirus in particular, and herpes simplex virus-1 to a
lesser extent, have both been associated with seizures in a number of reports (Jay et
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al., 1995; Suzuki et al., 2008), suggesting that viral infection and propagation may be
a common denominator in the alteration of early brain development.
The other two reports, both published in 2015, were unable to replicate our
findings. In the first (Shapiro et al., 2015), 14 distinct FCDIIB specimens obtained
from one surgical center were tested for HPV using PCR, in situ hybridization,
chromogenic in situ hybridization, and immunohistochemistry. HPV was not detected
by PCR, in situ hybridization, or chromogenic in situ hybridization. They expressed
concern about degraded DNA quality from tissue specimens, citing that 7 of the 14
specimens failed to generate an adequate amplicon, leaving the amplicons detected in
the other 7 samples subject to investigation. No mention was made as to the size of
the amplicons detected, or whether sequencing analysis was conducted. Shapiro and
colleagues conducted immunohistochemistry for p16INK4a, a cyclin-dependent
kinase inhibitor that is highly associated with HPV infection and used as a surrogate
marker of HPV infection, and found that 3 of 10 cases examined exhibited
immunoreactivity in balloon cells. HPV16 E6 immunohistochemistry was not
conducted. The discrepancy between the findings of Shapiro and colleagues and the
findings presented in Chapter 2 may be due to the variability in the rate of HPV
infection in various populations. The cohort used in this study came from a single
surgical center, which may be located in an area with low HPV exposure. The authors
are quick to point out that the animal model in our study did not contain dysmorphic
neurons and balloon cells. It is possible that the temporal expression of E6 (5 days)
was too short to result in morphological cellular deficits. Future studies will need to
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be conducted on postnatal mice to determine whether extended expression of E6 will
result in cytopathic effects concomitant with eventual seizures.
The third and last published report on FCDIIB and HPV probed 14 FCDIIB
specimens using 4 PCR primers for HPV DNA and antibodies against E6 (Coras et
al., 2015). Interestingly, all 14 specimens did not yield amplicons for HPV DNA, and
immunohistochemistry for E6 revealed weak staining in FCDIIB specimens as well
as in TSC specimens, attributed to a non-specific antibody and technical pitfalls when
using formalin-fixed paraffin-embedded brain tissues. No antibody controls were
conducted.
The lack of HPV detection by PCR by two of three research groups is puzzling. It is
possible that HPV DNA can exist as an episome or as an integrated genome in the
host cell nucleus. Perhaps HPV DNA that has successfully integrated is more
amenable to amplification by PCR. In the case of the former, detection would be
more likely using in situ hybridization, which Shapiro and colleagues conducted, with
no detection. Considering these differing findings, it is clear that the association
between HPV16 and FCDIIB is highly contested and will not be resolved without
more replication and research.
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Part 2
Region-specific astrocyte apoptosis/mechanism of astrocyte apoptosis
In human temporal lobe epilepsy as well as many seizure models, neuronal
cell death is evident in the hippocampus. For astrocytes, however, the literature on
apoptosis is very sparse. Since the time of Santiago Ramon y Cajal, astrocytes have
garnered a reputation for being hardier than neurons. Thus, our finding that astrocytes
undergo apoptosis in the hippocampus before the onset of behavioral seizures is both
novel and unprecedented. However, the mechanism underlying how loss of Slc25a12
leads to astrocyte cell death is still unknown.
Though we have made every effort to be rigorous in the analysis of the
timeline of the onset of both astrocyte apoptosis and behavioral seizures, one
possibility that we must consider is that seizure-like electroencephalographic (EEG)
abnormalities can be present without, and possibly before, the onset of behavioral
manifestations. However, measuring EEG in mouse pups under 2 weeks of age
remains a challenge due to the non-availability of small electrode devices and set ups
that accommodate the small size of pups. This limitation is reflected in the current
studies on Slc25a12 KO mice, which have not examined EEGs earlier than P15
(Gómez-Galán et al., 2012). However, even current studies raise more questions than
answers. Analyzing local field potentials (LFP) from hippocampus of wild type and
Slc25a12 KO mice aged P16 to P22, one group reported reduced LFP power in
Slc25a12 KO (Gómez-Galán et al., 2012), which is inconsistent with LFPs recorded
from other seizure models (Queiroz et al., 2009; Keller et al., 2010). They argued that
their LFPs are generated from hippocampal inhibitory interneurons by citing a deficit
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in gamma oscillations (waveforms propagated by GABAergic interneurons) as well
as a reduction in glutamic acid decarboxylase in Slc25a12 KO animals. Their
evidence suggests that Slc25a12 KO mice are deficient in GABA, implicating
GABAergic interneurons as the major driver of seizure genesis in Slc25a12 KO
animals. We submit that there may be global network deficiencies in Slc25a12 KO
mice, including contributions from GABAergic interneurons. However, our analyses
have pointed us toward the astrocyte as the major contributor in seizure genesis, as
GABAergic interneurons are largely unaffected by Slc25a12 KO.
To account for astrocytic cell death, one possibility to consider is the role of
astrocytic metabotropic glutamate receptor 5 (mGluR5). Astrocytic mGluR5 has a
demonstrated role in neuron-glia interactions, including the regulation of glutamate
reuptake (Vermeiren et al., 2006), and the expression of mGluR5 has also been shown
to be up-regulated in some models of epilepsy (Ferraguti et al., 2001; Aronica et al.,
2003). Additionally, in one study of murine primary cortical astrocyte cultures,
enhanced astrocytic mGluR5 expression resulting from oxygen glucose deprivation
resulted in the activation of phospholipase C and release of intracellular calcium
stores, leading to subsequent astrocyte cell death (Paquet et al., 2013). Though this
mechanism of astrocyte cell death has not been demonstrated in vivo, it is possible
that Slc25a12 KO cells experience partial glucose and oxygen deprivation by virtue
of their inability to maximally utilize glucose and oxygen (Pardo et al., 2011). This
partial deprivation may also explain the localized specificity of astrocyte cell death,
as brain regions vary in their metabolic demands, lending those regions with higher
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demands, such as the hippocampus, to be increasingly susceptible to perturbations in
glucose utilization.
One possibility that is appealing to speculate upon is that the expression of
cleaved caspase 3 and cleaved PARP in Slc25a12 KO astrocytes are not actually
indicators of cellular apoptosis, but rather, are expressed proteins that are used for
other cellular processes. Indeed, in addition to the role of apoptotic executioner
proteins in morphogenesis, cellular maturation, and differentiation, apoptotic
executioner proteins have also been demonstrated to be critical in compensatory
cellular proliferation and regeneration in many species, including mouse (Carlile et
al., 2004; Sztiller-Sikorska et al., 2009; Khalil et al., 2012; Miura, 2012). It is worth
noting that it is the uncleaved isoforms of these executioner caspases that are
involved in these various cellular processes. Therefore, given that the astrocytes in
Slc25a12 KO hippocampus exhibit robust cleaved caspase 3 and cleaved PARP,
proteins in the final common pathway of apoptosis, it is very likely the astrocytes in
Slc25a12 KO are undergoing apoptosis, and not facilitating the regulation of another
cellular process.

Astrocyte maturation
The increased expression of the immature astrocyte marker CD44 begs the
question of whether astrocytes are truly undergoing compensatory cell turnover or
whether astrocytes simply fail to mature properly. In support of the failure to achieve
maturation hypothesis, immature astrocytes consistently express reduced levels of
glutamate reuptake transporter GLT-1 in comparison to mature astrocytes (Furuta et
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al., 1997; Kugler and Schleyer, 2004). The fact that we see down-regulated levels of
GLT-1 in Slc25a12 KO hippocampus supports this hypothesis. However, it is worth
noting that we have also observed GLT-1 reduction in cortical protein lysates of
Slc25a12 KO brains (data not shown). The expression of CD44 in Slc25a12 KO
mouse brain, however, is restricted to the hippocampus. The presence of astrocyte
precursor cells in the region of the hippocampus where astrocyte apoptosis is
occurring is not coincident, and suggests that astrocytes undergo cell turnover in the
hippocampus to account for dying cells. Since it had been previously demonstrated
that astrocytes undergo local proliferation (Ge et al., 2012), this hypothesis is likely to
be a possibility.

Nuclear sequestration of ADK in Slc25a12 KO astrocytes
Our finding of enhanced localization of ADK-L in astrocytic nuclei is not
consistent with previous findings in mouse seizure models of increased ADK-S
localization in astrocytic cytoplasm. Furthermore, the discrepancy between the
immunohistochemical and Western data is puzzling. It is possible that putative
increases in nuclear ADK levels may be masked by the total amount of protein
present. The differential functions of the two ADK isoforms have not been elucidated
to date. So far, there is evidence to suggest that cytoplasmic ADK (ADK-S) may be
responsible for maintaining the balance of extracellular adenine nucleotides, while
nuclear ADK (ADK-L) contributes to epigenetic functions related to cell proliferation
(Cui et al., 2009). It is unclear whether nuclear localization of ADK shares the same
linkage to seizures as the previously established cytoplasmic ADK. Western assays
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on proteins from nuclear and cytoplasmic fractionation may help us resolve the true
extent of ADK expression and localization. However, it is appealing to speculate that
enhanced nuclear ADK-L in astrocytes may play a role in the enhancement of
astrocyte numbers we observed at P16, due to its putative effects on cell proliferation.
More studies, such as an astrocyte-specific ADK knockdown need to be conducted in
order to establish a mechanism of action linking nuclear ADK and astrocyte
proliferation.

ADK inhibition and treating seizures
Our data suggesting a link between astrocytes, ADK, and glutamate on
seizures prompted us to investigate whether reinstating adenosine-modulated
inhibitory tone would ameliorate behavioral seizures. To this extent, we plan to treat
Slc25a12 KO mice with the ADK inhibitor 4-amino-5-(3-bromophenyl)-7-(6morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, (ABT-702) and monitor them for
behavioral seizures, as described previously. ADK inhibitors have been used to
effectively treat and prevent seizures in animal models (Li et al., 2008). ABT-702 is
9-fold more potent than other ADK inhibitors such as 5-iodotubercidin (5-IT), and
works by binding to the phosphorylation site on adenosine where ADK would
normally bind, preventing it from interacting with ADK (Jarvis et al., 2000). It is
highly selective for this region, as it has not been demonstrated to bind to other sites
of adenosine interaction, such as with the A1, A2A, A3 receptors and the adenosine
transporter and deaminase binding regions, and its binding affinity for this site is high
(Ki = 1.4 ± 0.8 nM) (Jarvis et al., 2000). Though structure-activity relationships and
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computational modeling indicate that the half-life of ABT-702 is short at 2.42 hours,
it is longer than that of 5-IT and its high binding affinity suggests that though free
ABT-702 may be degraded in a short amount of time, the effects of bound ABT-702
are long lasting (Zheng et al., 2001).
Inhibiting the activity of ADK can result in sedation due to its effects on
increasing bioavailable adenosine. In a pilot study, we determined that 10 µg/kg (i.p.)
daily for young mouse pups resulted in minimal sedation that resolved itself within 12
hours. We will be administering this dose to mouse pups from P10-P16 and
monitoring for behavioral seizures using video recording. As previously speculated,
the link between ADK and seizures in Slc25a12 KO is tenuous considering its nuclear
localization. Furthermore, the ability of ABT-702 to cross the nuclear membrane is
unknown. If ABT-702 treatment results in minimal seizure amelioration, other
avenues such as activators of glutamate reuptake transporters or apoptotic inhibitors
can be explored. Evidence in the human and animal models of epilepsy literature cites
the efficacy of the ketogenic diet for ameliorating seizures related to metabolic
deficiencies (Beniczky et al., 2010; Noh et al., 2003; Yudkoff et al., 2005). In
Slc25a12 KO mice however, we have found that the ketogenic diet given to Slc25a12
KO pups through consumption by the dam, caused both pups and dams to lose weight
and may have contributed to premature pup death. There is evidence to suggest that
implementing the ketogenic diet during gestation alters brain structure and embryonic
organ growth leading to postnatal dysfunction (Sussman et al., 2013a; Sussman et al.,
2013b). Because the brain is still developing in neonatal mice, it is possible that
neonatal administration of ketogenic diet may contribute to altered brain structure and
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metabolic status as seen in pups treated in utero. In light of the astrocyte pathology
observed in Slc25a12 KO mice, we submit that a more astrocyte-centric approach to
therapy, such as ADK inhibitors, may be beneficial in treating seizures.

Other effects of Slc25a12 loss of function
Though most studies in the literature have focused on the role of Slc25a12 on
generating ATP, loss of Slc25a12 affects other cellular processes as well. As
mentioned previously, the role of Slc25a12 in cells is to shuttle reducing equivalents
(NADH), which are otherwise unable to cross the inner mitochondrial membrane,
into the mitochondria. When the ratio of NADH to NAD+ becomes high in the
cytosol, as it would if Slc25a12 was not functioning properly, glycolysis, which uses
NAD+ as an intermediate, will shut down. This results in a metabolic “double-hit,”
where the cell with deficient Slc25a12 is not only deficient in oxidative
phosphorylation, but also in the secondary mechanism of energy production,
glycolysis. This may result in a build up of lactate, which can be toxic to cells.
However, in our preliminary analysis, we (and others) did not observe an increase in
lactate production in vivo by magnetic resonance spectroscopy (Pardo et al., 2011) or
in vitro using conditioned media from mixed and astrocyte only cultures (data not
shown), indicating that there may be compensatory shuttling of reducing equivalents
by other transporters such as the glycerol-3-phosphate shuttle.
Another often over-looked function of Slc25a12 is its calcium-binding Nterminal. Slc25a12 requires the binding of calcium to facilitate its transporter
capabilities; in situations where Slc25a12 protein function or expression is reduced, it
124

is possible that the cell may experience a build-up of intra-mitochondrial calcium,
which can affect many processes, including cellular excitability. Imaging
mitochondria using calcium dyes would enable us to determine whether an increase in
intra-mitochondrial calcium is occurring, and additional experiments to determine the
morphology and localization of mitochondria would shed light on whether Slc25a12
loss of function results in additional mitochondrial dysfunction.
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Figure 4.1. Hypothesized model of HPV infection in utero.
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Figure 4.1. Hypothesized model of HPV infection in utero.
A single cell is infected transplacentally, where it proliferates and passes the viral
load on to its daughter cells. The infected cells activate the mTOR signaling cascade
and become cytomegalic,, leading to a focal malformation, surrounded by healthy
cells.
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